PosterSessionOnline

EUROPEAN HEMATOLOGY ASSOCIATION

19th Congress of EHA

12 - 15 June 2014 Milan

N. Poster

Poster title

Applicant name

Status


100-P	NOVEL STAT5B MUTATIONS AS DRIVERS OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Kontro Mika	Received

102-P	LEAFING THROUGH THE GENOME OF B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA BY NEXT-GENERATION SEQUENCING TECHNOLOGIES	Messina Monica	Received

103-P	IMPACT OF VIRUSES ON THE PATHOGENESIS OF SPORADIC CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: INTEGRATION AND PRESENCE OF 25.525 VIRAL GENOMES TESTED BY NEXT GENERATION SEQUENCING	Fischer Ute Luigia	Received

104-P	THE FIRST LNCRNA LANDSCAPE OF MAJOR GENETIC T-ALL SUBSETS AND GUILT-BY-ASSOCIATION ANALYSIS FOR ETP-ALL SPECIFIC LNCRNAS	Wallaert Annelynn Luigia	Received

105-P	PTEN MICRO-DELETIONS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ARE CAUSED BY ILLEGITIMATE RAG-MEDIATED RECOMBINATION EVENTS	Mendes Rui Therese	Received

106-P	CMYC-TRANSLOCATIONS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	la starza Roberta	Received

108-P	RNA-SEQ ANALYSIS TO DISSECT THE BIOLOGY OF EARLY RESPONSE TO TREATMENT IN HIGH RISK VS. STANDARD RISK CHILDHOOD BCP-ALL PATIENTS	Fazio Grazia Vu	Received

109-P	DARATUMUMAB TREATMENT ALONE OR IN COMBINATION WITH VINCRISTINE RESULTS IN THE INHIBITION OF TUMOR GROWTH AND LONG TERM SURVIVAL IN PRECLINICAL MODELS OF ACUTE LYMPHOCYTIC LEUKEMIA	Doshi Parul Giacoma	Received

110-P	EVALUATION OF TP53 MUTATIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): RESULTS FROM IRON (INTERLABORATORY ROBUSTNESS OF NEXT-GENERATION SEQUENCING) II STUDY	Brugnoletti Fulvia Ri	Received

111-P	INVESTIGATION OF PH-LIKE ALL BY GENE SET ENRICHMENT ANALYSIS AND IDENTIFICATION OF THEIR SPECIFIC EXPRESSION GENES	Iijima Kazutoshi Maria	Received

112-P	ROLE OF THE HYSTONE DEACETYLASE INHIBITOR GIVINOSTAT (ITF2357) IN TREATMENT OF CRLF2 REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA	savino Angela Maria	Received

113-P	TELOMERE DNA CONTENT AND TP53 STATE PROVIDE AN INSIGHT INTO GENOMIC INSTABILITY IN OLDER ADULT PATIENTS WITH ALL	Zakout Ghada Giacoma	Received

114-P	FUNCTIONAL STUDIES OF IK6 EXPRESSION SHED LIGHT ON THE COOPERATING MECHANISMS UNDERLYING THE GAIN OF MALIGNANCY IN B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA	zareian Nahid Giacoma	Received

115-P	ETV6-RUNX1 DE-REGULATES THE CYTOSKELETON AND MIGRATION PROPERTIES OF B CELL PROGENITOR CELLS	Palmi Chiara Giacoma	Received

116-P	ECTOPIC EXPRESSION OF THE HEDGEHOG PATHWAY LIGANDS SHH AND IHH IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL)	Dagklis Antonis Giacoma	Received

117-P	NON-INTENSIVE, BUT NO-INTERRUPTIONS PROTOCOL PROVIDES COMPARABLE RESULTS IN AYA AND OLDER ADULTS WITH PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: THE RUSSIAN ACUTE LYMPHOBLASTIC LEUKEMIA (RALL) STUDY GR	DROKOV Mikhail Giacoma	Received

119-P	THE POOR PROGNOSTIC VALUE OF IKZF1-DELETION IN CHINESE ADULT COMMON B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND THE SUPERIORITY OF STEM CELL TRANSPLANTATION OVER CHEMOTHERAPY FOR IKZF1 DELETED PATIENTS	Ruan Guo-Rui Chuan	Received

121-P	COMPARISON OF BONE MARROW AND PERIPHERAL BLOOD SAMPLES FOR MINIMAL RESIDUAL DISEASE MONITORING IN INFANTS WITH MLL-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA TREATED BY MLL-BABY PROTOCOL	Tsaur Grigory WAGEN	Received

124-P	NEGATIVE OUTCOME IN PTEN MUTATED ACUTE LYMPHOBLASTIC LEUKEMIA PEDIATRIC PATIENTS COULD BE MODULATED BY THE PRESENCE OF NOTCH1/FBXW7 MUTATIONS	Vega-Garcia Nerea Tang	Received

128-P	MLL REARRANGEMENT CONFERS THE POOREST PROGNOSIS AS THE SECOND MOST FREQUENT CHROMOSOME ABERRATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA, DATA FROM A SINGLE INSTITUTION IN CHINA	ZHOU Hongsheng Anders	Received

130-P	AML WITH EVI1 REARRANGEMENTS ARE CHARACTERIZED BY FREQUENT SF3B1 AND IKZF1 MUTATIONS	Lavallée Vincent-Philippe Wah	Received

131-P	SEQUENTIAL CARBOXY-TERMINAL PHOSPHORYLATION OF EVI1 UPON DNA DAMAGE	Schneider Marion R.	Received

132-P	SETBP1 MUTATIONS IN 106 PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASMS	fabiani Emiliano Anders	Received

133-P	FANCONI ANEMIA AND DNA-REPAIR GENE VARIANTS IN THERAPY-RELATED MYELOID NEOPLASMS	fabiani Emiliano Anders	Received

135-P	GENOMIC ANALYSIS OF THE CLONAL ORIGIN AND EVOLUTION OF ACUTE PROMYELOCYTIC LEUKEMIA IN A UNIQUE PATIENT WITH A VERY LATE (17 YEARS) RELAPSE	zhang Xiaolu Wah	Received

136-P	NOVEL MUTATED GENES IN ACUTE PROMYELOCYTIC LEUKEMIA IDENTIFIED BY WHOLE-EXOME SEQUENCING	Ibañez Mariam Wah	Received

139-P	IDENTIFICATION OF SOMATIC MUTATIONS OR FUSIONS BY RNA-SEQUENCING IN ACUTE MYELOID LEUKEMIA.	Viganò Ilaria Anders	Received

141-P	HALOPLEX TARGET DNA ENRICHMENT ALLOWS INVESTIGATION OF COPY NUMBER AND MUTATIONAL STATUS OF KEY GENES IN ACUTE MYELOID LEUKAEMIA WITH NORMAL KARYOTYPE	Bolli Niccolo	Received

143-P	THE CAMP RESPONSE ELEMENT BINDING PROTEIN (CREB) OVEREXPRESSION INDUCES MYELOID TRANSFORMATION IN ZEBRAFISH	Pigazzi Martina Anders	Received

144-P	POTENT COOPERATION BETWEEN THE NUP98-NSD1 FUSION AND THE FLT3-ITD MUTATION IN ACUTE MYELOID LEUKAEMIA INDUCTION	Thanasopoulou Angeliki Anders	Received

149-P	SERIAL TRANSPLANTATION AND IN VIVO MONITORING OF PATIENT-DERIVED XENOGRAFTS: AN ADVANCED PRECLINICAL MODEL TO STUDY DIVERSE GENETIC AML SUBGROUPS IN MICE	Vick Binje Anders	Received

151-P	MESENCHYMAL STEM CELLS (MSCS) OF AML PATIENTS HARBOR CHROMOSOMAL DEFECTS DISTINCT FROM THOSE OF LEUKEMIC CELLS.	Bernasconi Paolo R.	Received

152-P	ALTERATIONS IN MESENCHYMAL STROMAL PRECURSOR CELLS FROM THE BONE MARROW OF THE ACUTE MYELOID LEUKEMIA PATIENTS: NEWLY DIAGNOSED, AND BEFORE AND AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Shipounova Irina Anders	Received

157-P	LOW MST1 HIPPO KINASE EXPRESSION CONTRIBUTES TO DIFFERENTIATION DEFICIENCY IN AML CELLS	Wampfler Julian Anders	Received

158-P	NOVEL FUNCTION FOR THE RNA BINDING PROTEINS RBM38 AND DND1 IN AML CELL DIFFERENTIATION	Wampfler Julian Anders	Received

159-P	EARLY PERIPHERAL BLAST CELL CLEARANCE ASSESSED BY FLOW CYTOMETRY IN INDUCTION IS A NOVEL POWERFUL PROGNOSTIC INDICATOR IN ACUTE MYELOID LEUKEMIA: A NORTHERN ITALY LEUKEMIA GROUP (NILG) STUDY	Mannelli Francesco Anders	Received

161-P	PROGNOSTIC SIGNIFICANCE OF THE MRC CYTOGENETIC CLASSIFICATION COMPARED WITH THE EUROPEAN LEUKEMIANET (ELN) GENETIC RISK CLASSIFICATION SYSTEM IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)	Kadia Tapan	Received

162-P	WT1-ASSOCIATED MISSPLICING IN ACUTE MYELOID LEUKEMIA	wattel Eric R.	Received

163-P	VALIDATION OF EUROPEAN LEUKEMIA NET (ELN) GUIDELINES FOR CYTOGENETICALLY NORMAL AML IN ASSOCIATION WITH NPM1 AND FLT3-ITD MUTATIONS: FURTHER STRATIFICATION FOCUSING ON WT1 EXPRESSION	Yoon Jae-Ho Anders	Received

164-P	WT1 MUTATIONS ARE SECONDARY EVENTS IN AML, SHOW VARYING FREQUENCIES WITHIN GENETIC SUBGROUPS AND DIFFERENT IMPACT ON PROGNOSIS	Krauth Maria Wah	Received

166-P	MULTICENTER SURVEY ON OUTCOME OF AML REFRACTORY TO FIRST INDUCTION CHEMOTHERAPY IN THE LAST 4 YEARS (2010-2013).	Candoni Anna	Received

167-P	PRETREATMENT RISK SCORE FOR PREDICTION OF EARLY DEATH AFTER INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MYELOID LEUKEMIA	Djunic Irena Wah	Received

168-P	TRAIL AND ITS RECEPTORS EXPRESSION ON LEUKEMIC CELLS OF PATIENTS WITH AML1-ETO POSITIVE ACUTE MYELOID LEUKEMIA	Liu Li Gen	Received

170-P	HIGH EXPRESSION LEVEL OF PRAME GENE IS FAVORABLE PROGNOSTIC FACTOR IN ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS	Misyurin Vsevolod Gen	Received

171-P	ASXL1 MUTATIONS DEFINE A SUBGROUP OF AML PATIENTS WITH DISTINCT GENE EXPRESSION PROFILE AND POOR PROGNOSIS: A META-ANALYSIS OF 3311 ADULT AML PATIENTS	Shivarov Velizar Gen	Received

172-P	INCIDENCE AND PROGNOSTIC IMPACT OF FLT3 AND NPM1 MUTATIONS IN ACUTE MYELOID LEUKEMIA AND CKIT AND NRAS GENE MUTATIONS IN RUNX1/RUNX1T1 AML	Petrova Ekaterina R.	Received

175-P	EARLY ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR OF RELAPSE OR SURVIVAL IN ACUTE MYELOID LEUKEMIA	Yamazaki Etsuko R.	Received

176-P	TREATMENT WITH RADIATION, CHEMOTHERAPY, OR BOTH DEMONSTRATES SIMILAR OUTCOMES IN PATIENTS WITH ISOLATED MYELOID SARCOMA THAT MAY NOT BE DIFFERENT THAN DE NOVO ACUTE MYELOID LEUKEMIA	Feller Faye Gen	Received

177-P	ACUTE MYELOID LEUKEMIA IN PATIENTS 70 AND ABOVE. AZACITIDINE VERSUS INTENSIVE CHEMOTHERAPY	De La Fuente	Received

178-P	LOW DOSE GEMTUZUMAB OZOGAMICIN PLUS FLAI AS INDUCTION THERAPY IN CD33-POSITIVE AML. DEFINITIVE RESULTS AND LONG TERM OUTCOME OF A PHASE III MULTICENTER PROSPECTIVE CLINICAL TRIAL (NCT.00909168).	Candoni Anna	Received

182-P	AZACITIDINE AND INTENSIVE CHEMOTHERAPY IN THE TREATMENT OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA: A META-ANALYSIS	Gao Sujun R.	Received

185-P	PHASE I STUDY OF OPB-51602, AN INHIBITOR OF STAT3 PHOSPHORYLATION, IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES	TERUI Yasuhito Fuente	Received

189-P	CHARACTERIZATION OF GLOBAL HYDROXYMETHYLATION LEVELS IN AML	Kroeze Leonie Fuente	Received

194-P	VARIABLE REACTIVE OXYGEN SPECIES LEVELS ARE ASSOCIATED WITH ANERGY IN CLL	Linley Adam Fuente	Received

196-P	MONOCYTE/MACROPHAGE LINEAGE CELLS SIGNIFICANTLY INFLUENCE THE SURVIVAL AND PROLIFERATION OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS	Bertilaccio Maria Teresa	Received

198-P	LENALIDOMIDE INDUCES A PRO-INFLAMMATORY PHENOTYPE IN NURSE-LIKE CELLS DERIVED FROM CHRONIC LYMPHOCYTIC LEUKEMIA	Fiorcari Stefania Teresa	Received

200-P	DIFFERENT CLL STEREOTYPED SUBSETS, VARYING TELOMERE LENGTHS: A MEASURE OF DISTINCT PROLIFERATIVE HISTORIES LINKED WITH UNIQUE CLINICOBIOLOGICAL FEATURES	Stamatopoulos Kostas R.	Received

201-P	SKEWING OF THE T-CELL RECEPTOR REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: WHAT LIES BENEATH?	Vardi Anna Teresa	Received

203-P	INTRA-PATIENT CLONAL AND SUBCLONAL HETEROGENEITY OF CHRONIC LYMPHOCYTIC LEUKEMIA: EVIDENCES FROM CIRCULATING AND LYMPH NODAL COMPARTMENTS	Del Giudice Ilaria	Received

204-P	OVERCOMING RESISTANCE TO THE NOVEL BH3-MIMETIC ABT-199 IN A CLL LYMPH NODE MODEL; THE ROLE OF ABL AND BTK	thijssen Rachel Ilaria	Received

206-P	IMMUNOHISTOCHEMICAL ANALYSIS OF IL-6, IL-8/CXCR2 AXIS, TYROSINE P-STAT–3 AND SOCS-3 IN CLL LYMPH NODES: CORRELATION WITH MICROVASCULAR CHARACTERISTICS, CLINICAL FEATURES AND PROGNOSIS	Sachanas Sotirios Ilaria	Received

207-P	EXPRESSION AND FUNCTIONAL ACTIVITY OF THE TNFR-SUPERFAMILY MEMBER DEATH RECEPTOR 3 IN CHRONIC LYMPHOCYTIC LEUKEMIA B CELLS ACTIVATED BY THE BCR	Cavallini Chiara Ilaria	Received

208-P	VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INCREASES CELL MIGRATION THROUGH INTERACTION WITH THE CXCR4/SDF1 AXIS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL)	Ballester Garcia Sandra	Received

209-P	ANALYSIS OF IMMUNOGLOBULIN GENE REARRANGEMENTS IN CHINESE AND ITALIAN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Marinelli Marilisa Sandra	Received

211-P	SRC INHIBITORS DOWNREGULATE CD20 AND MODULATE THE ACTIVITY OF THE CD20 PROMOTER	Winiarska Magdalena R.	Received

212-P	COMPLEX ACTIVATION OF ANGIOGENIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA: EVIDENCE FROM CIRCULATING ANGIOGENIC CYTOKINES.	Smolej Lukas Sandra	Received

213-P	CHRONIC LYMPHOCYTIC LEUKEMIA CELL CAPACITY OF EXPRESSING AND RESPONDING TO SURFACE IGM (S-IGM) OR S-IGD PREDICTS DISEASE PROGRESSION AND IS ASSOCIATED WITH SPECIFIC MIRNA/MRNA SIGNATURES	Recchia Anna Grazia	Received

214-P	B-CELL RECEPTOR SIGNALLING ENHANCES GLYCOLYSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA	Valle Argos Beatriz	Received

215-P	NICHEFORMING STROMAL ELEMENTS OF BONE MARROW AND LYMPH NODES IN CLL	Semenova Natalya Beatriz	Received

216-P	DISTRIBUTION OF CIRCULATING RESIDUAL NORMAL B-CELLS AND OTHER IMMUNE CELLS IN ADVANCED-STAGE B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ACCORDING TO THE NUMBER OF PRIOR TREATMENT LINES RECEIVED	Barrena Susana	Received

217-P	THE INFLUENCE OF BENDAMUSTINE USED ALONE OR IN COMBINATION WITH RITUXIMAB ON APOPTOSIS AND THE EXPRESSION OF SOME APOPTOSIS-REGULATING PROTEINS DEPENDING ON THE IGVH MUTATIONAL STATUS OF CLL CELLS	Korycka-Wolowiec Anna	Received

218-P	DECREASED DKK-1 LEVELS IN CHRONIC LYMPHOCYTIC LEUKEMIA AT INITIAL DIAGNOSIS MIGHT BE PREDICTIVE OF A HIGHER MORTALITY	Pamuk Gulsum R.	Received

219-P	MRD ANALYSIS IN BONE MARROW ASPIRATE AT 3 MONTHS AFTER TREATMENT IS THE OPTIMAL RESPONSE ASSESSMENT FOR CLL AND CAN PREDICT SUSTAINED MRD-NEGATIVE REMISSION INDEPENDENT OF ADVERSE PROGNOSTIC MARKERS	Rawstron Andy Beatriz	Received

220-P	NOT ALL IGHV3-21 CLL ARE EQUAL: SUBSET #2 DISPLAYS A DISTINCTIVE CLINICOBIOLOGICAL PROFILE WITH REMARKABLE SIMILARITIES TO SUBSET #169, ITS CLOSE IMMUNOGENETIC RELATIVE	Baliakas Panagiotis Beatriz	Received

221-P	IMMUNOGLOBULIN HEAVY VARIABLE GENES AND ALLELES: NEW ENTITIES, NEW NAMES AND IMPLICATIONS FOR RESEARCH AND PROGNOSTICATION IN CLL	XOCHELLI Aliki Wah	Received

225-P	THE DUAL PI3K/MTOR INHIBITOR PF-04691502 INDUCES SUBSTANTIAL APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS INDEPENDENTLY OF PROGNOSTIC MARKERS	Blunt Matthew Beatriz	Received

226-P	INDIRECT INDUCTION OF REGULATORY T CELLS ACCOMPANIES IMMUNE RESPONSES DURING VACCINATION OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH SHORT, RHAMM-DERIVED, MHC-I- RESTRICTED PEPTIDE	Zaleska Joanna Beatriz	Received

228-P	A B-CELL EPIGENETIC SIGNATURE DEFINES THREE BIOLOGICAL SUBGROUPS OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH MAJOR CLINICAL IMPACT	Martin-Subero Jose I.	Received

232-P	THE GENE EXPRESSION RESPONSE TO INTERLEUKIN-4 AND ITS DIFFERENTIAL MODULATION BY NFKB CORRELATE WITH ZAP70 IN CHRONIC LYMPHOCYTIC LEUKEMIA	Parrado Antonio R.	Received

233-P	ORAL FCR INDUCES HIGHER COMPLETE REMISSION RATES AND MRD NEGATIVITY IN UNTREATED CLL THAN PREVIOUS REPORTS OF INTRAVENOUS THERAPY: COMBINED RESULTS OF THE NCRI ADMIRE AND ARCTIC TRIALS	Munir Talha R.	Received

234-P	DEVELOPMENT AND VALIDATION OF COMPREHENSIVE CLL MUTATION DETECTION PANEL USING ION TORRENT NEXT GENERATION SEQUENCING PLATFORM	Lozanski Gerard Wah	Received

238-P	LATE ONSET NEUTROPENIA IS A COMMON COMPLICATION OF FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) THERAPY AND IS ASSOCIATED WITH SUBSTANTIAL MORBIDITY AND HOSPITALIZATION	Ho Prahlad Wah	Received

240-P	?2-MICROGLOBULIN IS A DYNAMIC MARKER OF PROGNOSIS DURING TREATMENT OF CLL WITH FCR OR IBRUTINIB-BASED REGIMENS.	Thompson Philip Beatriz	Received

241-P	FIRST-LINE TREATMENT STRATEGIES FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: PRELIMINARY RESULTS OF A NETWORK META-ANALYSIS	Rancea Michaela R.	Received

245-P	A SYSTEMATIC REVIEW AND EVIDENCE SYNTHESIS OF RANDOMISED CONTROLLED TRIALS (RCT) FOR THE TREATMENT OF RELAPASED OR REFRACTORY CHRONIC LYMPHOCTYIC LEUKEMIA (CLL)	Quigley Joan Beatriz	Received

246-P	PROSPECTIVE VALIDATION OF A RISK SCORE BASED ON BIOLOGICAL MARKERS FOR PREDICTING PFS IN BINET STAGE A CLL PATIENTS: RESULTS OF THE MULTICENTER O-CLL1-GISL STUDY	Gentile Massimo Beatriz	Received

247-P	SALVAGE TREATMENT WITH BENDAMUSTINE, OFATUMUMAB, HIGH-DOSE METHYLPREDNISOLONE (BOMP) IN HIGH-RISK R/R CLL : INTERIM RESULTS OF THE FRENCH CLL INTERGROUP (GCFLLC/MW - GOELAMS) ICLL01 PHASE 2 TRIAL.	Tournilhac Olivier Beatriz	Received

248-P	NOVEL GENE MUTATIONS IN CHINESE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS	xia Yi R.	Received

251-P	THE ROLE OF ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RICHTER´S SYNDROME - META-ANALYSIS	Antic Darko Beatriz	Received

253-P	BLOOD STREAM INFECTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: STABLE DISTRIBUTION BUT WITH INCREASED MORTALITY RATE?	Kjellander Christian Beatriz	Received

254-P	TARGETING OF STAT3 AND STAT5 BY A NOVEL DRUG- COMBINATION EMPLOYING PONATINIB AND BARDOXOLONE METHYL (CDDO-ME) LEADS TO SYNERGISTIC EFFECTS IN BCR/ABL-T315I-MUTATED CELLS IN PH+ CML	Gleixner Karoline Beatriz	Received

255-P	CD62L EXPRESSION ON T CELLS IS DECREASED IN PATIENTS WITH EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) AND PREDICTS RESPONSE TO THERAPY WITH FRONTLINE NILOTINIB	Sopper Sieghart Beatriz	Received

256-P	LASP1 IS A NOVEL BCR-ABL SUBSTRATE AND A PHOSPHORYLATION-DEPENDENT BINDING PARTNER OF CRKL IN CHRONIC MYELOID LEUKEMIA	Frietsch Jochen R.	Received

257-P	DNA METHYLTRANSFERASE 1-DRIVEN HYPER-METHYLATION OF ? CATENIN ANTAGONIST CHIBBY1 IS NOT AN EPIGENETIC MARK OF CHRONIC MYELOID LEUKEMIA RESISTANCE TO IMATINIB	Leo Elisa Beatriz	Received

258-P	MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) AS POTENTIAL IMMUNE ESCAPE MECHANISM IN CML PATIENTS	Giallongo Cesarina Beatriz	Received

259-P	BIN1 AND RIN1 MODULATION IN CHRONIC MYELOID LEUKEMIA	Trino Stefania Beatriz	Received

260-P	PROMOTER METHYLATION OF THE TUMOR SUPPRESSOR GENES ON THE SHORT ARM OF CHROMOSOME 1 IN CHRONIC MYELOGENOUS LEUKEMIA	MORI Naoki R.	Received

263-P	IMPACT OF CLONAL EVOLUTION ON THE OVERALL SURVIVAL OF PATIENTS WITH CML TREATED WITH IMATINIB: EXPERIENCE OF ONE CENTER	Kotlyarchuk Kostyantyn Beatriz	Received

264-P	A FUNCTIONAL POLYMORPHISM IN THE 3´ UNTRANSLATED REGION OF THE ARHGAP26 GENE CONFERS AN INCREASED RISK OF CHRONIC MYELOID LEUKEMIA AND CAUSES ILLEGITIMATE REGULATION BY MICRORNA-18A-3P	Dzikiewicz-Krawczyk Agnieszka R.	Received

266-P	MUTATED SETBP1 INCREASES THE NUCLEAR LOCALIZATION OF PP2A AND ITS PHOSPHORYLATED FORM	Redaelli Sara Beatriz	Received

268-P	GENE EXPRESSION PROFILING OF CD34+/LIN- CELLS OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AT DIAGNOSIS IDENTIFIES NEW GENES RELATED TO THE NUMBER OF CD34+/LIN- CELLS DURING NILOTINIB TREATMENT	Trojani Alessandra R.	Received

269-P	EXPRESSION LEVELS OF CERAMIDE-GENERATING AND CLEARANCE GENES IN NEWLY DIAGNOSED AND TYROSINE KINASE INHIBITOR-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS: AN ATTEMPT TO FIND NOVEL TARGETS	Kartal Yandim Melis	Received

270-P	MIRNA-30E TARGETS BCR-ABL1 AND SENSITIZES K562 CELLS TO IMATINIB TREATMENT	Granot Galit Beatriz	Received

271-P	ANTILEUKEMIC EFFECT OF PLK INHIBITOR AND IN COMBINATION WITH ABL TYROSINE KINASE INHIBITORS AGAINST BCR-ABL-POSITIVE CELLS	Okabe Seiichi	Received

273-P	TYROSINE KINASE INHIBITORS DO NOT AFFECT EXPRESSION OF DNA METHYLTRANSFERASES AND GLOBAL METHYLATION LEVEL IN CHRONIC MYELOID LEUKEMIA CELLS	Stoklosa Tomasz Beatriz	Received

276-P	DECLINING ROLE OF DISEASE TRANSORMATION AS A CAUSE OF DEATH IN CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB IN EARLY CHRONIC PHASE: A LONG-TERM ANALYSIS BY THE GIMEMA CML WP	Castagnetti Fausto	Received

277-P	NEW MOLECULAR MARKERS OF CML PROGRESSION	Misyurin Vsevolod Beatriz	Received

278-P	PROGNOSIS FOR CML PATIENTS WITH >10% BCR-ABL AFTER 3 MONTHS OF IMATINIB DEPENDS ON THE INITIAL RATE OF BCR-ABL DECLINE	Branford Susan Melis	Received

283-P	AGE AND DIGITAL-PCR ANALYSIS PREDICT RELAPSES OF CML PATIENTS FOLLOWING PROGRAMMED IMATINIB INTERRUPTION IN Q-RT-PCR NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENTS	Mori Silvia Beatriz	Received

284-P	EARLY RESPONSE OF RADOTINIB THERAPY MAY PREDICT LONG-TERM OUTCOMES IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH RESISTANCE OR INTOLERANCE TO BCR-ABL1 TKIS: 24 MONTH UPDATE OF PHASE 2 TRIAL	Kim Sung-Hyun Melis	Received

285-P	MR4.5 AT POST-TRANSPLANT 3 MONTHS WAS A PREDICTIVE FACTOR FOR LONG-TERM OUTCOMES IN THE PATIENTS UNDERWENT ALLOGENEIC SCT IN CML CP	Lee Sung-Eun Melis	Received

286-P	MOLECULAR MONITORING USING PERIPHERAL BLOOD COMBINED WITH BONE MARROW AT 3 MONTHS OR 6 MONTHS PROVIDES A BETTER PREDICTOR OF OUTCOMES FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA	Jiang Qian Melis	Received

287-P	BCR-ABL1 RATIO LOG REDUCTION IS A BETTER PREDICTOR OF MAJOR MOLECULAR RESPONSE (MMR) THAN 10% RATIO CUT-OFF AT 3 MONTHS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS	Del Orbe Rafael	Received

288-P	GENEXPERT BCR-ABL1/ABL1 MONITOR TEST (IS) FOR ROUTINE MONITORING OF CHRONIC MYELOID LEUKEMIA PATIENTS	Balatzenko Gueorgui Beatriz	Received

290-P	DISCONTINUATION OF IMATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH UNDETECTABLE MOLECULAR RESIDUAL DISEASE FOR AT LEAST 1 YEAR.	OH Yunjeong Beatriz	Received

291-P	CHANGES OF QUALITY OF LIFE AFTER CESSATION OF IMATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH UNDETECTABLE MOLECULAR RESIDUAL DISEASE	Oh Sukjoong Rafael	Received

293-P	LENALIDOMIDE MODIFIES THE BEHAVIOR OF MESENCHYMAL STROMAL CELLS (MSC) FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITH 5Q- (MDS-5Q-)	Muntion Sandra Beatriz	Received

294-P	IMPAIRED LINEAGE PRIMING AND PROLIFERATIVE POTENTIAL OF BONE MARROW MESENCHYMAL STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES ARE ASSOCIATED WITH ABNORMAL WNT SIGNALING PATHWAY	Pontikoglou Charalampos Beatriz	Received

295-P	INCREASED EXPRESSION OF INTERFERON RELATED GENES IN THE BONE MARROW MICROENVIRONMENT OF MYELODYSPLASTIC SYNDROMES	Kim Miyoung Beatriz	Received

297-P	CHROMOTHRIPSIS IN BONE MARROW CELLS OF ADULT PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) WITH COMPLEX KARYOTYPES.	Zemanova Zuzana Beatriz	Received

300-P	ANTI-ERYTHROBLAST AUTOIMMUNITY IN EARLY MYELODYSPLASTIC SYNDROMES: ENHANCEMENT OF EPO/EPO-R SYSTEM AND PRO-APOPTOTIC EFFECT	zaninoni Anna Beatriz	Received

303-P	DISTURBANCE OF EPIGENETIC STATUS IN STROMAL CELLS COULD BE INDUCED BY INTERACTION WITH MDS/AML-INITIATING CELLS.	Kobune Masayoshi Wah	Received

304-P	INDEPENDENT MULTICENTRIC STUDY ON THE INTEREST OF OGATA SCORE AND OF CD5, CD7 AND CD56 IN MDS AND MDS/MPS IN REAL LIFE.	GUERIN Estelle Rafael	Received

305-P	SELECTIVE EFFECT OF LENALIDOMIDE ON CELL CYCLE AND INOSITIDE-DEPENDENT ERYTHROID SIGNALLING IN DEL(5Q) CELLS AND MYELODYSPLASTIC SYNDROMES (MDS)	Follo Matilde Y.	Received

306-P	POSSIBLE PREVENTIVE ROLE OF CXCR4 AND ACTIVE CASPASE 3 IN LEUKEMIC EVOLUTION OF MYELODYSPLASTIC SYNDROMES	Nikolova Veselka Y.	Received

307-P	NEW GERMLINE TERT GENE MUTATIONS IN APLASTIC ANEMIA / HYPOCELLULAR MYELODYSPLASTIC SYNDROMES	Matteucci Caterina Y.	Received

308-P	IS THERE A RELATIONSHIP BETWEEN BONE MARROW CYTOMORPHOLOGY AND FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES?	GUERIN Estelle Rafael	Received

309-P	MOLECULAR CYTOGENETIC CHARACTERIZATION OF T(2;5)(P16.2;Q33.1) LEADING TO PDGFRB/SPTBN1 GENE FUSION IN A CASE OF MDS RESPONSIVE TO IMATINIB MESYLATE	KOUMBI Daphne Y.	Received

310-P	THE INTERPLAY BETWEEN OXIDATIVE STRESS AND EPIGENETIC PROFILE IN MYELOID NEOPLASIAS	Gonçalves Ana Cristina	Received

311-P	IMMUNE SURVEILLANCE IMPACTS PROGNOSIS: REGULATORY T CELLS AND PROGENITOR B CELLS ARE INDEPENDENT PREDICTORS OF SURVIVAL IN LOW AND INTERMEDIATE RISK MDS	kahn Josephine Rafael	Received

312-P	DEFERASIROX CHELATION THERAPY IN TRANSFUSION DEPENDENT MDS PATIENTS. A "REAL WORLD" REPORT FROM TWO REGIONAL ITALIAN REGISTRIES : GRUPPO ROMANO MIELODISPLASIE AND REGISTRO BASILICATA	Maurillo Luca Cristina	Received

313-P	THE INCIDENCE OF COMORBIDITIES AT THE TIME OF DIAGNOSIS IN PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROMES: OVERVIEW THROUGH THE "REL" ("RETE EMATOLOGICA LOMBARDA") DISEASE REGISTRY	Riva Marta Rafael	Received

314-P	MYOCARDIAL TISSUE CHARACTERIZATION BY CARDIAC MR IMAGING IN MYELODYSPLASTIC SYNDROMES	Meloni Antonella Rafael	Received

315-P	PRE AND POST-TREATMENT SERUM FERRITIN LEVELS IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES RECEIVING ERYTHROPOIESIS STIMULATING AGENTS	Leitch Heather Rafael	Received

316-P	VALIDATION OF LOW RISK PROGNOSTIC SCORING SYSTEM (LR-PSS) IN 318 PATIENTS WITH LOWER RISK IPSS MYELODYSPLASTIC SYNDROME FROM A SINGLE CENTER.	POMARES MARIN Helena	Received

317-P	MRI SURVEY IN TRANSFUSION-DEPENDENT AND NON-TRANSFUSION-DEPENDENT MDS PATIENTS	Meloni Antonella Rafael	Received

318-P	THE IMPACT OF TRANSFUSION DEPENDENCY ON THE OUTCOME OF PATIENTS WITH VERY LOW AND LOW RISK MYELODYSPLASTIC SYNDROME ACCORDING TO THE IPSS-R.	Arnan Montse Cristina	Received

319-P	CALRETICULIN MUTATION WAS RARELY DETECTED IN PATIENTS WITH MYELODYSPLASTIC SYNDROME	Hou Hsin-An Cristina	Received

323-P	THE USE OF MEDICAL CLAIMS TO ASSESS INCIDENCE, DIAGNOSTIC PROCEDURES AND INITIAL TREATMENT AMONG PATIENTS WITH MYELODYSPLASTIC SYNDROMES IN THE NETHERLANDS	Dinmohamed Avinash Rafael	Received

325-P	THE IMPORTANCE OF CYTOGENETIC SCORING SYSTEM IN MYELODYSPLASTIC SYNDROME	Drevojankova Bronislava Rafael	Received

326-P	DAPK AND TRAIL RECEPTORS METHYLATION STATUS IN MYELODYSPLASTIC SYNDROMES PATIENTS	Gonçalves Ana Cristina	Received

327-P	IDENTIFICATION OF NOVEL ALTERNATIVE SPLICE VARIANTS OF SIRTUINS IN MULTIPLE MYELOMA: A BIOLOGICALLY RELEVANT INDICATOR OF POOR OUTCOME	Michele Cea Cristina	Received

328-P	BONE MARROW CD14+ CELLS SHOW DIFFERENT TRANSCRIPTIONAL PROFILES IN MULTIPLE MYELOMA (MM) AS COMPARED TO SMOLDERING MM AND MGUS: OVEREXPRESSION OF IL-21R AND ITS INVOLVEMENT IN OSTEOCLASTOGENESIS.	Giuliani Nicola Cristina	Received

329-P	HOW DOES LENALIDOMIDE/DEXAMETHASONE REDUCES RISK OF TRANSFORMATION IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA? LONGITUDINAL IMMUNOPHENOTYPIC PROFILING OF IMMUNE EFFECTOR CELLS FROM THE QUIREDEX TRIAL	Paiva Bruno Cristina	Received

330-P	LONG-TERM RESULTS OF THE GIMEMA VEL-03-096 TRIAL IN MULTIPLE MYELOMA PATIENTS RECEIVING VTD CONSOLIDATION AFTER ASCT: IMPACT OF MRD KINETICS ON DURATION OF RESPONSE AND OVERALL SURVIVAL	Ferrero Simone Cristina	Received

331-P	THE EXPRESSION OF HIGH LEVELS OF CRBN ISOFORM LACKING IMIDS BINDING DOMAIN PREDICTS FOR A LOWER PROBABILITY OF HIGH-QUALITY RESPONSE TO IMID-BASED UPFRONT THERAPY IN NEWLY DIAGNOSED MYELOMA PATIENTS	Terragna Carolina Cristina	Received

332-P	ACTIVATED AND EXPANDED NATURAL KILLER (NKAE) CELLS KILL MULTIPLE MYELOMA (MM) CLONOGENIC PLASMA CELLS THROUGH NKG2D AND NKP30 RECEPTORS AND THEIR LIGANDS	Leivas Alejandra Cristina	Received

333-P	CIRCULATING MIR-34A AND MIR-130A AS BIOMARKERS OF EXTRAMEDULLARY DISEASE	Kubiczkova Lenka Rafael	Received

335-P	DOES CHARACTERISTIC PHENOTYPE FOR PLASMA CELL LEUKAEMIA EXIST?	Rihova Lucie Cristina	Received

336-P	GENE EXPRESSION PROFILING AND COPY NUMBER ALTERATIONS OF CIRCULATING CLONOTYPIC B CELLS OF MULTIPLE MYELOMA NEWLY DIAGNOSED PATIENTS REVEALS PATHWAYS POTENTIALLY INVOLVED IN THE DISEASE PERSISTENCE	Martello Marina Cristina	Received

337-P	CAN GENOME ARRAY SCREENING REPLACE FISH AS A FRONT-LINE TEST IN MULTIPLE MYELOMA?	Gancheva Katya Cristina	Received

338-P	COMPARATIVE STUDY OF GENE EXPRESSION PROFILING BETWEEN ASYMPTOMATIC AND SYMPTOMATIC WALDENSTRÖM´S MACROGLOBULINEMIA PATIENTS	Jiménez Cristina Cristina	Received

339-P	TRANSCRIPTIONAL REGULATION OF ALTERNATE SPLICING BY DP1 AND THEIR FUNCTIONAL IMPACT IN MULTIPLE MYELOMA	fulciniti Mariateresa Cristina	Received

340-P	DOWNREGULATION OF TELOMERASE ACTIVITY IN RESPONSE TO NEW GENERATION OF PROTEASOME INHIBITORS (EPOXOMICIN AND MG132) IN MULTIPLE MYELOMA CELLS	Muchtar Eli Helena	Received

341-P	HSP90 INHIBITOR-DRUG CONJUGATES (HDC) WITH ANTITUMOR AGENTS TARGETING HEMATOLOGICAL MALIGNANCES	Rao Patricia	Received

342-P	TOLL-LIKE RECEPTOR ACTIVATION PROMOTES MULTIPLE MYELOMA CELL GROWTH AND SURVIVAL BY SUPPRESSION OF ENDOPLASMIC RETICULUM STRESS FACTOR CHOP	BAGRATUNI Tina Cristina	Received

343-P	ENDOPLASMIC RETICULUM STRESS-RELATED GENE EXPRESSION CAN PREDICT RESPONSE TO BORTEZOMIB IN MYELOMA	Tomoko Narita Helena	Received

344-P	MODIFYING DNA REPAIR PATHWAYS IN CHEMOTHERAPY BY GENOTOXIC DRUGS – TOWARDS PERSONALIZED MYELOMA THERAPY	Gkotzamanidou Maria Rafael	Received

346-P	TARGETING ANGIOGENESIS IN MULTIPLE MYELOMA: A POSSIBLE ROLE FOR EPHA3 AND A SPECIFIC MONOCLONAL ANTIBODY	caivano Antonella Cristina	Received

348-P	THE USE OF SINGLE AGENT ZOLEDRONIC ACID PREVENTS THE DEVELOPMENT OF BONE DISEASE COMPLICATIONS IN MYELOMA PATIENTS WITH ASYMPTOMATIC RELAPSES WITH NO DEMONSTRATED EFFECT ON SYMPTOMS PROGRESSION	GARCIA-SANZ Ramon Helena	Received

349-P	LENALIDOMIDE-DEXAMETHSONE (RD) VS MELPHALAN-LENALIDOMIDE-PREDNISONE (MPR) VS CYCLOPHOSPHAMIDE-PREDNISONE-LENALIDOMIDE (CPR) IN ELDERLY COMMUNITY-BASED NEWLY DIAGNOSED MYELOMA PATIENTS	Magarotto Valeria Cristina	Received

354-P	GERIATRIC ASSESSMENT PREDICTS SURVIVAL AND RISK OF SERIOUS ADVERSE EVENTS FOR ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.	Mina Roberto Cristina	Received

357-P	EFFICACY AND SAFETY OF THREE SUBCUTANEOUS BORTEZOMIB COMBINATIONS IN ELDERLY, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS	Cerrato Chiara Cristina	Received

358-P	RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HISTONE DEACETYLASE 6 INHIBITOR, IS ACTIVE AND WELL TOLDERATED IN COMBINATION WITH LENALIDOMIDE OR BORTEZOMIB IN PATIENTS WITH REFRACTORY MYELOMA	Havens Tyce Cristina	Received

360-P	PRELIMINARY SAFETY AND EFFICACY OF TH-302, AN INVESTIGATIONAL HYPOXIA-TARGETED DRUG, AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR MM)	Hansen Laura Cristina	Received

361-P	POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) WITH DELETION DEL(17P) AND/OR TRANSLOCATION T(4;14).	Leleu Xavier Rafael	Received

362-P	PERSISTENT PFS BENEFIT AND SUPERIOR PFS2 WITH VTD VS TD FOR NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE, MULTIPLE MYELOMA (MM) PATIENTS: UPDATED ANALYSIS OF GIMEMA MMY-3006 STUDY	Pantani Lucia Cristina	Received

366-P	OUTCOMES OF PRIMARY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS IN PATIENTS TREATED UPFRONT WITH BORTEZOMIB OR LENALIDOMIDE AND THE IMPORTANCE OF RISK ADAPTED STRATEGIES	Kastritis Efstathios Cristina	Received

370-P	A PHASE 1 STUDY OF FILANESIB (ARRY-520) WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE (DEX) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)	Walker Duncan Rafael	Received

374-P	IDENTIFICATION OF REVERSIBLE RENAL DAMAGE AND EARLY MARKERS OF RESPONSE TO CHEMOTHERAPY IN AL AMYLOIDOSIS: A STUDY ON 732 PATIENTS	Palladini Giovanni Cristina	Received

375-P	MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) IS ASSOCIATED WITH A 30% INCREASED RISK OF DYING AT 8 YEARS OF FOLLOW-UP: RESULTS FROM A SCREENED CROSS-SECTIONAL POPULATION-BASED STUDY	Lindqvist Ebba Cristina	Received

379-P	BORTEZOMIB OR THALIDOMIDE INCORPORATED INTO AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS NOVEL AGENT-BASED TREATMENTS FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A CASE-MATCH COMPARISON	tacchetti Paola Cristina	Received

380-P	CAN 24-HOUR URINE COLLECTION BE REPLACED BY AN EARLY MORNING SAMPLE FOR BENCE JONES PROTEIN DETECTION AND QUANTIFICATION?	Milani Paolo Cristina	Received

381-P	PHASE II TRIAL OF LENALIDOMIDE, DEXAMETHASONE AND CYCLOPHOSPHAMIDE (LENDEXAL) FOR PREVIOUSLY UNTREATED PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS	Cibeira M. Teresa	Received

382-P	THE ADDITION OF BORTEZOMIB TO STANDARD MELPHALAN/DEXAMETHASONE IMPROVES THE QUALITY OF RESPONSE BUT DOES NOT REDUCE THE RATE OF EARLY DEATHS IN AL AMYLOIDOSIS: A MATCHED CASE CONTROL COMPARISON	Palladini Giovanni Teresa	Received

384-P	PLATELET MICROPARTICLE PROCOAGULANT AND PROANGIOGENIC FEATURES IN ESSENTIAL THROMBOCYTHEMIA (ET)	Gamba Sara Teresa	Received

386-P	MORGANA IS A NEW ONCOSUPPRESSOR IN CHRONIC MYELOID LEUKEMIA	MOROTTI Alessandro Helena	Received

388-P	INTRACELLULAR CALCIUM DEPOSITS AND STORE OPERATED CALCIUM ENTRY IN CD34+ CELLS FROM PATIENTS WITH MYELOFIBROSIS CARRYING A CALR MUTATION	Rosti Vittorio Teresa	Received

389-P	VEGF-INDUCED CA2+ SIGNALS ARE DERANGED IN ENDOTHELIAL PROGENITOR CELLS FROM PATIENTS WITH MYELOFIBROSIS CARRYING JAK2 MUTATIONS	Moccia Francesco Teresa	Received

392-P	GATA1 IS OVEREXPRESSED IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND IT IS NORMALIZED BY ANAGRELIDE TREATMENT.	RINALDI Ciro Helena	Received

393-P	IMPORTANCE OF CALR MUTATIONS IN THE DIAGNOSIS OF PRIMARY MYELOFIBROSIS.	Zamora Lurdes Teresa	Received

394-P	THE SOMATIC MUTATION RATE IS INCREASED IN PATIENTS WITH CLASSICAL MYELOPROLIFERATIVE NEOPLASMS WHO HAVE A SECOND PRIMARY TUMOR.	Notaro Rosario Teresa	Received

395-P	MOUSE LEUKEMIC TRANSFORMATION IN PMF XENOGRAFT MODEL REVEALS PARACRINE REGULATION IN DISEASE PROGRESSION	Triviai Ioanna Helena	Received

396-P	CYTOGENETIC INVESTIGATION OF G-CSF-STIMULATED PERIPHERAL BLOOD IN PATIENTS WITH PRIMARY MYELOFIBROSIS	Lozynskyy Rosyslav Teresa	Received

397-P	CHARACTERIZATION OF MPL-MUTATED MYELOID NEOPLASMS: A REVIEW OF 224 MPL+ CASES	Lin Keming Helena	Received

398-P	DEREGULATION OF MICRORNA146B-1 IS ASSOCIATED WITH MYELOFIBROSIS IN MYELOPROLIFERATIVE NEOPLASMS	Ha Jung Sook	Received

399-P	HIGH THROUGHPUT SCREENING ON PERIFPERHAL BLOOD CD34 CELLS WITH A FLOW CYTOMETRY AUTOMATED PLATFORM (EXVITECH), TO IDENTIFY SENSITIVITY TO RUXOLITINIB IN MYELOFIBROSIS PATIENTS	Arenas Alicia Teresa	Received

400-P	HEMATOPOIETIC PROGENITOR CELLS EXPRESSING VE-CADHERIN ARE DETECTABLE IN THE SPLEEN OF PATIENTS WITH MYELOFIBROSIS AND ARE IN CLOSE CONTACT WITH MICROVESSELS	Rosti Vittorio Teresa	Received

401-P	EVALUATION OF THE ASSOCIATION BETWEEN JAK2 46/1 HAPLOTYPE AND MYELOPROLIFERATIVE NEOPLASMS	Ha Jung Sook	Received

404-P	OUTCOME OF JAK2/MPL/CALR TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	Panagiota Victoria Teresa	Received

406-P	SURVIVAL IN PATIENTS WITH FAMILIAL AND SPORADIC MYELOPROLIFERATIVE NEOPLASMS	Hultcrantz Malin Teresa	Received

408-P	CLINICAL CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASM WITH CALRETICULIN MUTATIONS	Krähling Tünde Teresa	Received

409-P	JAK2 V617F ALLELE BURDEN AND VASCULAR COMPLICATION OCCURRENCE RISK IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS	Borowczyk Martyna	Received

411-P	UTILITY OF BONE MARROW HISTOLOGY AND IMMUNOHISTOCHEMISTRY IN THE DIAGNOSTIC WORK-UP OF EOSINOPHILIA OF UNKNOWN SIGNIFICANCE	Metzgeroth Georgia Teresa	Received

412-P	INFLUENCE OF IL-28B AND IL-6 GENETIC POLYMORPHISM ON IFN-ALFA TREATMENT OUTCOME IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL TROMBOCYTHEMIA	Lindgren Marie Teresa	Received

413-P	DYNAMICS OF CALR MUTANT ALLELE BURDEN IN ESSENTIAL THROMBOCYTHEMIA PATIENTS	Bellosillo Beatriz Teresa	Received

415-P	TREATMENT OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS WITH PEGYLATED INTERFERON ALPHA-2A: A PROSPECTIVE MONOCENTER COHORT STUDY.	De Stefano Valerio	Received

416-P	SPECIFIC DETECTION OF CALR-MUTATED MYELOPROLIFERATIVE NEOPLASMS BY IMMUNOSTAINING	Rotunno Giada Helena	Received

418-P	MICROARRAY ANALYSIS OF CHROMOSOME 11Q IN A GROUP OF AGGRESSIVE LYMPHOMA: THE PARTIAL DUPLICATION OF 11Q AS A CYTOGENETIC MARKER OF SUBSET OF THE GREY ZONE BETWEEN BURKITT´S (BL) AND DIFFUSE LARGE B-C	Grygalewicz Beata Helena	Received

419-P	THE B CELL ANTIGEN RECEPTOR IS CRITICAL FOR BURKITT LYMPHOMA GROWTH VIA GSK3? REGULATION	Varano Gabriele Valerio	Received

420-P	CONCOMITANT INHIBITION OF EZH1 AND EZH2 IMPAIRS GROWTH OF C-MYC DRIVEN B CELL LYMPHOMAS	Petrocelli Valentina Valerio	Received

422-P	ACTIVATED SUMOYLATION MACHINERY IS A HALLMARK OF BURKITT LYMPHOMA WITH NEW THERAPEUTIC IMPLICATIONS	Höllein Alexander Helena	Received

423-P	CD19-TARGETING LIPOSOMES CONTAINING RAPAMYCIN INDUCE AUTOPHAGIC CELL DEATH IN BURKITT´S LYMPHOMA CELLS	Sato Tsutomu Sook	Received

425-P	HIGH EXPRESSION OF MIRNA-199A_1 AND MIRNA-497_1 IS ASSOCIATED WITH BETTER OVERALL SURVIVAL IN AGGRESSIVE NON-HODGKIN´S LYMPHOMA	TROPPAN Katharina Sook	Received

429-P	CONSTITUTIVE ACTIVATION OF THE DNA DAMAGE RESPONSE PATHWAY IS A NOVEL THERAPEUTIC TARGET IN DIFFUSE LARGE B-CELL LYMPHOMA.	Derenzini Enrico Sook	Received

430-P	FOXO1 TRANSCRIPTION FACTOR MEDIATES TOXICITY OF SYK INHIBITION IN DLBCL.	Kiliszek Przemyslaw Sook	Received

431-P	KINOME REPROGRAMMING IN DLBCL BY THE BTK-SPECIFIC INHIBITOR ONO-4059 HIGHLIGHTS SYNERGISTIC COMBINATIONS FOR CLINICAL APPLICATION	Kozaki Ryohei Valerio	Received

432-P	PRECLINICAL EVALUATION OF A NOVEL, HIGHLY POTENT AND SELECTIVE PI3K-DELTA INHIBITOR, CPL-302-201, FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES	Stanczak Aleksandra Valerio	Received

435-P	DIGITAL IMAGE ANALYSIS OF KI-67 FOR RISK STRATIFICATION OF PATIENTS WITH MANTLE CELL LYMPHOMA	Blaker Yngvild Nuvin	Received

437-P	ABSOLUTE MONOCYTE AND LYMPHOCYTE COUNT IN FOLLICULAR LYMPHOMA: PROGNOSTIC ROLE IN SURVIVAL OUTCOME EVALUATION	SACCHI Stefano Nuvin	Received

438-P	BRIEF RITUXIMAB, BENDAMUSTINE, MITOXANTRONE (R-BM) INDUCTION PLUS RITUXIMAB CONSOLIDATION IN ELDERLY DE NOVO ADVANCED STAGE FOLLICULAR LYMPHOMA: FINAL RESULTS OF A STUDY BY FONDAZIONE ITALIANA LINFOMI	Boccomini Carola Valerio	Received

439-P	BENDAMUSTINE IS NOT ASSOCIATED WITH AN INCREASE IN INFECTIONS – SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	Gafter-Gvili Anat Helena	Received

440-P	EXPRESSION OF CD200 AND CD148 IN LEUKEMIC B-CELL CHRONIC LYMPHOPROLIFERATIVE DISORDERS	Fan Lei Valerio	Received

441-P	ABEXINOSTAT (S78454) A HISTONE DEACETYLASE INHIBITOR, IN PATIENTS WITH REFRACTORY OR RELAPSED HODGKIN´S LYMPHOMA, NON-HODGKIN LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA: PRELIMINARY PHASE II RESULTS.	broussais Florence Nuvin	Received

442-P	HIGH-DOSE CLARITHROMYCIN IS A FEASIBLE AND ACTIVE MONOTHERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY EXTRANODAL MARGINAL ZONE LYMPHOMA [EMZL]: RESULTS FROM THE "HD-K" PHASE II TRIAL	Ferreri Andres Valerio	Received

443-P	EPIDEMIOLOGY OF NON-HODGKIN LYMPHOMA IN THE US: DISTRIBUTION BY SUBTYPES, DEMOGRAPHICS, AND TRENDS FROM 1998-2011	GO Ronald Nuvin	Received

446-P	DROPLET PCR: A NEW SENSITIVE METHOD FOR DETECTING BRAFV600E MUTATION IN HAIRY CELL LEUKEMIA	GALIMBERTI Sara Valerio	Received

448-P	CLINICAL COMPARABILITY OF BCD-020 TO INNOVATOR RITUXIMAB IN PATIENTS WITH INDOLENT NON-HODGKIN´S LYMPHOMA	Chernyaeva Ekaterina Nuvin	Received

449-P	OCCURRENCE OF CHRONIC THERAPY-RELATED HYPOGAMMAGLOBULINAEMIA IN INDOLENT NON HODGKIN LYMPHOMA: SINGLE CENTRE EXPERIENCE.	Pulsoni Alessandro Valerio	Received

450-P	PERIPHERAL BLOOD LYMPHOCYTE/MONOCYTE RATIO (LMR) >2 IS ASSOCIATED WITH BETTER OUTCOME IN FOLLICULAR LYMPHOMA (FL): A SINGLE CENTRE EXPERIENCE	Belotti Angelo Nuvin	Received

456-P	PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY MANTLE CELL LYMPHOMA	Wasserman Matthew Valerio	Received

457-P	FREQUENCY OF SURVEILLANCE COMPUTED TOMOGRAPHY IN NON-HODGKIN LYMPHOMA AND THE RISK OF SECONDARY PRIMARY MALIGNANCIES	Chien Sheng Hsuan	Received

459-P	MYD88 (L265P) MUTATION IS AN INDEPENDENT PROGNOSTIC FACTOR IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA	Fernandez Maria Concepción	Received

463-P	APOPTOTIC POLYMORPHISMS ARE INVOLVED IN AGGRESSIVENESS AND PROGNOSIS OF DIFFUSE LARGE B-CELL LYMPHOMA	Borsarelli Carvalho Brito	Received

469-P	EFFICALY OF M-NHL-BFM-90 TREATMENT PROTOCOL FOR PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA	LUKINA Anna Helena	Received

471-P	NON PEGILATED LIPOSOMAL DOXORUBICIN IS SAFE AND EFFECTIVE AS PART OF R-COMP IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AND MODERATE/SEVERE HEART DISEASE. RESULTS OF HEART01 TRIAL BY THE FONDAZIONE	Spina Michele Brito	Received

472-P	HIGH DOSES OF ANTIMETABOLITES FOLLOWED BY HIGH-DOSE SEQUENTIAL CHEMOIMMUNOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT IN SYSTEMIC B-CELL LYMPHOMAS WITH CNS INVOLVEMENT: A MULTICENTER PHASE II TRIAL	Ferreri Andres Brito	Received

473-P	R-ESHAP-LENALIDOMIDE AS SALVAGE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA CANDIDATES TO STEM-CELL TRANSPLANTATION: UPDATED RESULTS OF A PHASE IB GELTAMO STUDY	REDONDO Alba Brito	Received

474-P	NCCN-INTERNATIONAL PROGNOSTIC INDEX (NCCN-IPI) IS A POTENTIAL PROGNOSTIC MODEL IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA	Xu Pengpeng Hsuan	Received

475-P	RITUXIMAB-CHOP PLUS INTRATHECAL METHOTREXATE AND CONTRALATERAL TESTIS IRRADIATION IN UNTREATED PRIMARY TESTICULAR DIFFUSE LARGE B-CELL LYMPHOMA: LONG-TERM RESULTS OF THE IELSG-10 TRIAL	Chiappella Annalisa Brito	Received

476-P	THE NOVEL ROLE OF BONE MARROW INVOLVEMENT DETECTED BY BOTH STAGING AND INTERIM FDG PET-CT IN DIFFUSE LARGE B-CELL LYMPHOMAS	Xu Wei Hsuan	Received

477-P	MIR-155 IS ASSOCIATED WITH THE LEUKEMOGENIC POTENTIAL OF CLASS IV G-CSFR IN CD34+ PROGENITOR CELLS	Figueiredo Constanca Hsuan	Received

478-P	THE ROLE OF EPITHELIAL TO MESENCHYMAL TRANSITION IN THE REMODELING OF LUNG INJURY INDUCED BY ACUTE GRAFT-VERSUS-HOST DISEASE	Liu Qifa Hsuan	Received

482-P	RECIPIENT BATF3 DEPENDENT DENDRITIC CELLS SUPPRESS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER EXPERIMENTAL ALLOGENEIC BONE MARROW TRANSPLANTATION	Radsak Markus Hsuan	Received

483-P	DISRUPTED TOLL-LIKE RECEPTOR SIGNALING OF INTESTINAL EPITHELIUM IN INTESTINAL GRAFT-VERSUS-HOST DISEASE	Liu Qifa Hsuan	Received

484-P	CYCLOSPORIN A DOES NOT IMPAIR EARLY GRANULOCYTE EFFECTOR FUNCTION	Teschner Daniel Brito	Received

487-P	ACTIVATED MONOCYTE-PHAGOCYTES PROBABLY INITIATE THE ONSET OF PRE-ENGRAFTMENT SYNDROME (PES) FOLLOWING UMBILICAL CORD BLOOD TRANSPLANTATION	wang Jian Brito	Received

488-P	INFLUENCE OF HLA-G POLYMORPHISM ON VIRAL REACTIVATION AND OVERALL SURVIVAL AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION	Metafuni Elisabetta Hsuan	Received

489-P	MYELOID DERIVED SUPPRESSOR CELLS ARE MOBILIZED BY G-CSF IN MICE AND MEN	WETZKO Katrin Hsuan	Received

490-P	GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION AFFECTS THE EXPRESSION OF TH1/TH2 CHEMOKINES AND THEIR RECEPTORS	Liu Qifa Hsuan	Received

491-P	GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION AFFECTS THE EXPRESSION OF REGULATORY GAMMA DELTA T CELLS	Liu Qifa Hsuan	Received

495-P	ALDEHYDE DEHYDROGENASE-BRIGHT CELLS CORRELATED WITH THE COLONY FORMING UNIT-GRANULOCYTE/MACROPHAGE ASSAY OF THAWED CORD BLOOD UNITS	Lee Hye Ryun	Received

496-P	A MACHINE LEARNING BASED MODEL FOR PREDICTION OF NRM 100 DAYS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT). A EUROPEAN REGISTRY DATA MINING STUDY.	SHOUVAL Roni Ryun	Received

497-P	CONTRASTING EFFECT OF MISSING SELF MODEL AND ACTIVATING DONOR KIR GENES WITH RELEVANT HLA LIGAND IN RECIPIENTS ON PREVENTING RELAPSE AFTER T-CELL-REPLETE HAPLOIDENTICAL TRANSPLANTATION IN CML	Zhao Xiang-Yu Ryun	Received

498-P	IMPACT OF SMOKING ON THE NON-RELAPSE MORTALITY, THE OVERALL SURVIVAL, AND THE INCIDENCE OF SECOND CANCERS AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES	Spina Francesco Brito	Received

500-P	IMPACT OF GRAFT SOURCE ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ADULTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA.	Nakajima Yuki Ryun	Received

501-P	A POTENTIAL BENEFIT OF INHIBITORY KIR-MISMATCHED UNMANIPULATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOLLOWING TBI-BASED CONDITIONING IN ADULT PATIENTS WITH AML	Yahng Seung-Ah Brito	Received

506-P	DECREASE OF INVASIVE FUNGAL DISEASE IN OUR CENTER WITH THE USE OF VORICONAZOLE AS ANTIFUNGAL PROPHYLAXIS IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION	CHIC ACEVEDO Carolina	Received

507-P	LONG-TERM SURVIVAL IN PATIENTS RECEIVING RHEPO FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	JASPERS Aurélie Carolina	Received

508-P	SEQUENTIAL THIRD-PARTY MESENCHYMAL STROMAL CELL THERAPY FOR REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE	Sanchez-Guijo Fermin Carolina	Received

509-P	PLASMA PROHNPS ARE SPECIFIC EARLY MARKERS OF NEUTROPHIL ENGRAFTMENT IN PATIENTS UNDERGOING HIGH-DOSE CHEMOTHERAPY, AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANTATION	Glenthøj Andreas Ryun	Received

511-P	HIGH-DOSE PREPARATION WITH THIOTEPA/ETOPOSIDE/ARA-C/MELPHALAN (TEAM) VS BEAM FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTOHSCT) IN LYMPHOMA: A RETROSPECTIVE STUDY FROM THE EBMT	Dreger Peter Brito	Received

514-P	THE IMPACT OF PRETRANSPLANT IRON CHELATING THERAPY WITH DEFERASIROX ON THE OUTCOME IN PATIENTS WITH SEVERE APASTIC ANEMIA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION	Lee Sung-Eun Ryun	Received

516-P	THE RUNX-PU.1 PATHWAY PRESERVES NORMAL AND AML/ETO9A LEUKEMIC STEM CELLS	Staber Philipp Brito	Received

517-P	THE TISSUE INHIBITOR OF METALLOPROTEINASES-1 (TIMP-1) MODULATES HUMAN HSPC FUNCTIONS THROUGH CD63/PI3K/AKT SIGNALING	Rossi Lara Carolina	Received

518-P	LACK OF GLUCOCORTICOID-INDUCED LEUCINE ZIPPER (GILZ) RESULTS IN B CELL LYMPHOPROLIFERATIVE DISORDER IN MICE	Bereshchenko Oxana Carolina	Received

524-P	HISTONE DEACETYLACE INHIBITOR VORINOSTAT REDUCES KIT EXPRESSION BY DEREGULATION OF THE TRANSCRIPTIONAL COMPLEX AND INDUCTION OF HETEROCHROMATIN	Abdulkadir Hani Carolina	Received

525-P	ASSOCIATION OF AN IMPAIRED BONE MARROW VASCULAR MICROENVIRONMENT WITH PRIMARY FAILURE OF PLATELET ENGRAFTMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Kong Yuan Ryun	Received

526-P	REGULATION OF B LYMPHOPOIESIS BY SIGNAL-TRANSDUCING ADAPTOR PROTEIN-2, STAP-2	Ichii Michiko	Received

527-P	IMPACT OF COLD SHOCK PROTEIN YBX1 ON HEMATOPOIETIC STEM CELL DEVELOPMENT AND FUNCTION	Heidel Florian Ryun	Received

529-P	IMMUNOMODULATION EFFECTS OF MESENCHYMAL STEM CELLS IN THE TREATMENT OF REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE	Liu Qifa Ryun	Received

531-P	MUTATIONAL ANALYSIS OF BONE MARROW MESENCHIMAL STROMAL CELLS IN MYELOID MALIGNANCIES	fabiani Emiliano Carolina	Received

532-P	ADDITION OF PLERIXAFOR TO G-CSF IMPROVES THE GRAFT CONTENT IN SIDE POPULATION (SP) WITH IMMATURE PHENOTYPE IN PATIENTS THAT FAILED TO RESPOND WELL TO G-CSF ALONE.	Bijou Fontanet Carolina	Received

533-P	THE IRON CHELATOR DEFERASIROX AFFECTS REDOX SIGNALING IN HEALTHY HEMATOPOIETIC STEM CELLS	Piccoli Claudia Carolina	Received

534-P	INTERACTIONS BETWEEN MULTIPOTENT MESENCHYMAL STROMAL CELLS AND HEMATOPOIETIC PROGENITOR CELLS ALTER AFTER INTERLEUKIN 1 BETA ADMINISTRATION	Drize Nina Ryun	Received

536-P	MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITS OVEREXPANSION OF IMMATURE ERYTHROID CELLS IN THE SPLEEN DURING CHRONIC PSYCHOLOGICAL STRESS	Budec Mirela Ryun	Received

538-P	THE SPECTRUM OF ADULT´S PARVOVIRUS B19 INFECTION IN HOSPITAL ACCORDING TO THE CLINICAL BACKGROUND: REPORT OF A SINGLE CENTER EXPERIENCE AND PROPOSALS FOR THE CLINICAL PRACTICE.	Wagner-Ballon Orianne Carolina	Received

539-P	CONTINUOUS ERYTHROPOIETIC ACTIVITY OF EPOETIN BETA PEGOL IN A GENE-MODIFIED MOUSE MODEL FOR ERYTHROPOIETIN-DEFICIENCY ANAEMIA	Suzuki Norio Ryun	Received

540-P	CATION LEAK ANALYSIS OF ABCB6 MUTANTS IN FAMILIAL PSEUDOHYPERKALEMIA	Andolfo Immacolata Carolina	Received

541-P	GENETIC MARKERS AND FETAL HEMOGLOBIN (HBF) PRODUCTION: ASSOCIATION STUDY IN DELTABETA THALASSEMIA	De La Fuente	Received

542-P	MITOGEN-STIMULATED DIRECT ANTIGLOBULIN TEST IN PATIENTS WITH HEREDITARY SPHEROCYTOSIS	zaninoni Anna Fuente	Received

544-P	THE REDUCTION OF PEROXIREDOXINS ACTIVITY ARE CORELATED WITH THE INCREASE OF REACTIVE OXYGEN SPECIES (ROS) AND CELL HEMOLYSIS OBSERVED IN PATIENTS WITH HEMOLITIC ANEMIAS	Anderson Cunha	Received

545-P	HYPERTHERMIA INDUCES ERYPTOSIS IN HEREDITARY SPHEROCYTOSIS	Crisp Renee Ryun	Received

546-P	HAMP GENE MUTATION ASSOCIATED WITH JUVENILE HEMOCHROMATOSIS IN BRAZILIAN FAMILY	Santos Paulo Ryun	Received

547-P	HB CERVANTES, HB MARAÑÓN, HB LA MANCHA AND HB GOYA: DESCRIPTION OF FOUR NEW HEMOGLOBINOPHATIES	De La Fuente	Received

549-P	INFLUENCE OF HBG2 XMNI POLYMORPHISM ON HBF LEVELS IN PORTUGUESE BETA-THALASSEMIA CARRIERS	Manco Licinio Ryun	Received

550-P	MOLECULAR CHARACTERIZATION OF THE MUTATIONS CAUSING G6PD DEFICIENCY AMONG EGYPTIAN CHILDREN WITH GENOTYPE - PHENOTYPE CORRELATION	ADLY Amira Fuente	Received

551-P	EXTRAMEDULLARY HEMATOPOIESIS (EMH) IS ASSOCIATED WITH A THALASSAEMIA INTERMEDIA-LIKE PATTERN OF MYOCARDIAL AND LIVER IRON LOADING IN REGULARLY POLYTRANSFUSED THALASSAEMIA PATIENTS	Meloni Antonella Ryun	Received

552-P	MAGNETIC RESONANCE IMAGING T2 AND R2* TECHNIQUES REFLECT RENAL HEMOSIDEROSIS IN PATIENTS WITH THALASSEMIA AND SICKLE-CELL DISEASE; CORRELATIONS WITH SERUM FERRITIN AND MARKERS OF HEMOLYSIS	Christoulas Dimitrios Fuente	Received

553-P	HEPATIC FIBROSIS AND CIRRHOSIS IN PATIENTS WITH THALASSAEMIA MAJOR IS ASSOCIATED WITH PRESENT AND HISTORICAL IRON OVERLOAD, AGE, AND ACTIVE HEPATITIS C INFECTION	Pasricha Sant-Rayn Ryun	Received

554-P	FIBROSCAN FOR THE DETECTION OF LIVER FIBROSIS IN HAEMOGLOBINOPATHY PATIENTS REQUIRING CHRONIC TRANSFUSION THERAPY	Gasiorowski Robin Fuente	Received

555-P	EFFECT OF SPLENECTOMY ON CARDIAC IRON AND FUNCTION IN DIFFERENT TRANSFUSION-DEPENDENT PATIENTS	Meloni Antonella Ryun	Received

557-P	VENOUS THROMBOEMBOLISM IN SICKLE CELL DISEASE: PREVALENCE AND PATIENT CHARACTERISTICS.	van Hamel Parsons	Received

560-P	SOLUBLE FMS-LIKE TYROSINE KINASE-1 IN YOUNG PATIENTS WITH SICKLE CELL DISEASE: RELATION TO HEMOLYSIS-ASSOCIATED COMPLICATIONS	Tantawy Azza Parsons	Received

561-P	GROWTH DIFFERENTIATION FACTOR-15 IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE: RELATION TO HEMOLYSIS, IRON OVERLOAD AND VASCULAR COMPLICATIONS	Tantawy Azza Parsons	Received

563-P	OUTCOMES OF A COHORT OF CHILDREN WITH HEMOGLOBINOPATHY RECEIVING ORAL IRON CHELATORS FOR TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN TURKEY: 24-MONTH FOLLOW-UP	Antmen Bulent Parsons	Received

564-P	NON-TRANSFERRIN BOUND IRON REVISITED: NOW THAT ITS POTENTIAL TOXICITY IS ESTABLISHED, HOW CAN ITS MEASUREMENT HELP TO GUIDE CHELATION	BERDOUKAS Vasilios Ryun	Received

565-P	CHARACTERIZATION OF RARE ?LPHA-GLOBIN GENE MUTATIONS IN THAILAND	Uaprasert Noppacharn Parsons	Received

568-P	VARICELLA-ZOSTER VIRUS INFECTIONS IN IMMUNOCOMPROMISED PATIENTS; COMPARISON OF HEMATOLOGY – ONCOLOGY PATIENTS AND OTHER CHRONIC DISEASES	Yoruk Asim Ryun	Received

569-P	CHANGING OF PLATELET DERIVED MICROPARTICLES, SCUBE-1 AND IL-1? IN CHILDREN WITH DENGUE INFECTION	Sosothikul Darintr Ryun	Received

571-P	ROLE OF PROPHYLAXIS WITH LAMIVUDINE IN MAINTENANCE TREATMENT WITH RITUXIMAB IN NON HODGKIN LYMPHOMA CD20+	Cerchione Claudio Parsons	Received

572-P	THE IMPACT OF HEPATITIS B VIRUS (HBV) INFECTION ON PROGNOSIS OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AND THE OCCURRENCE OF HEPATITIS FLARES AFTER WITHDRAWAL OF PROPHYLACTIC ANTIVIRAL TREATMENT	Law Man Fai	Received

573-P	PREVALENCE, CHARACTERISTICS AND MANAGEMENT OF OCCULT HEPATITIS B VIRUS INFECTION (OBI) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS. MONOCENTRIC EXPERIENCE.	Laurenti Luca Fai	Received

574-P	SAFE RITUXIMAB ADMINISTRATION TO NHL PATIENTS WITH CONCOMITANT HBV ACTIVE INFECTION: THE RISK OF HBV REACTIVATION SHOULD NOT PREVENT US TO DELIVER OPTIMAL TREATMENT	Zilioli Vittorio Brito	Received

575-P	A RETROSPECTIVE ANALYSIS OF CYTOMEGALOVIRUS DISEASE IN PATIENTS WITH MALIGNANT LYMPHOMAS WHO HAVE NOT RECEIVED HEMATOPOIETIC STEM CELL TRANSPLANTATION	Sato Kazuya Fai	Received

576-P	TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION DOESN´T INCREASE THE RISK OF SYMPTOMATIC CYTOMEGALOVIRUS REACTIVATION IN MYELOMA PATIENTS IN THE ERA OF NOVEL AGENTS: A SINGLE INSTITUTION STUDY	MARCHESI Francesco Ryun	Received

577-P	IMPACT OF NOSOCOMIAL VIRAL INFECTION IN CHILDREN UNDERGOING INTENSIVE CHEMOTHERAPY OR STEM CELL TRANSPLANTATION FOR HEMATOLOGIC OR MALIGNANT DISEASE	Yagasaki Hiroshi Brito	Received

578-P	CLINICAL CHARACTERISTICS AND OUTCOMES OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTS	Gijima Desire Fai	Received

579-P	THE CLINICAL SPECTRUM AND OUTCOMES OF HUMAN HERPESVIRUS 6-RELATED INFECTIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Hegerova Livia Ryun	Received

580-P	ANALYSIS OF PNEUMONIA IN ACUTE LEUKEMIA: A PROSPECTIVE STUDY BY THE "RETE EMATOLOGICA LOMBARDA" (REL)	Mancini Valentina Fai	Received

581-P	INFECTIONS IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME ON TREATMENT WITH AZACYTIDINE: EXPERIENCE OF A SINGLE CENTER.	Lakhwani Sunil Ryun	Received

582-P	ASSESSMENT OF INFECTION EVENTS IN AZACITIDINE (AZA) TREATMENT FOR MYELODYSPLASTIC SYNDROME (MDS) AND ACUTE MYELOID LEUKEMIA (AML). A SINGLE CENTRE EXPERIENCE.	Romero Pilar Fai	Received

584-P	ADMISSION OF PATIENTS WITH HEMATOLOGIC MALIGNANCES TO INTENSIVE CARE UNITS	Badior Margarida Fai	Received

585-P	PROSPECTIVE OBSERVATIONAL STUDY ON CHEMOTHERAPY- INDUCED NAUSEA AND VOMITING (CINV) FOR HEMATOLOGIC MALIGNANCY PATIENTS AND PRIMARY CARE MEDICAL STAFF´S PERCEPTION BY THE CINV STUDY GROUP OF JAPAN	Yoshida Isao Brito	Received

587-P	BUFFY COAT POOLED PLATELETS CRYOPRESERVED IN DIMETHYL-SULPHOXIDE WITH A NEW SYSTEM PRESERVE THEIR IN VITRO FUNCTION UP TO 9 MONTHS	siragusa Sergio Fai	Received

588-P	HEMOSTATIC FUNCTION AND BIOMARKERS OF ENDOTHELIAL DAMAGE BEFORE AND AFTER PLATELET TRANSFUSION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Larsen Anne Fai	Received

590-P	ASSESSING RISK OF BLEEDING IN THROMBOCYTOPENIC PATIENTS REQUIRING PLATELET TRANSFUSION PRIOR TO INVASIVE PROCEDURES	Al Zaabi Mohamed	Received

591-P	RED CELL BLOOD GROUP GENOTYPING IN A COHORT OF BLOOD DONORS: FOCUS ON THE DUFFY ANTIGEN SYSTEM	Colpo Anna Brito	Received

593-P	RED BLOOD CELL ALLOIMMUNIZATION IN 18 – 50 YEAR OLD TRANSFUSED WOMEN A 3 YEAR STUDY	MONCHARMONT Pierre Brito	Received

594-P	RED BLOOD CELLS ALLOIMMUNIZATION IN POLYTRANSFUSED PATIENTS.	Lucea Irene Mohamed	Received

595-P	IDENTIFICATION OF ABCB6 GENETIC VARIANTS WITH LOW OR ABSENT PROTEIN EXPRESSION AS THE GENETIC BASIS OF HIGH FREQUENCY BLOOD GROUP ANTIGEN LANGEREIS	Koszarska Magdalena	Received

596-P	ANALYSIS OF ADVERSE REACTIONS IN VOLUNTARY WHOLE BLOOD DONORS: EXPERIENCE FROM A GREEK BLOOD CENTRE	Girtovitis Fotios Mohamed	Received

599-P	EVALUATION OF BILIARY INJURY IN NEWBORNS WITH ABO INCOMPATIBILITY	El-Farrash Rania	Received

602-P	FEASIBILITY OF ROMIPLOSTIM DISCONTINUATION IN ADULT TPO-MIMETIC RESPONSIVE PATIENT WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): AN OBSERVATIONAL RETROSPECTIVE REPORT IN REAL LIFE CLINICAL PRACTICE	Carpenedo Monica Brito	Received

604-P	A PROSPECTIVE, MULTICENTER, OPEN-LABEL STUDY OF RECOMBINANT HUMAN THROMBOPOIETIN ON PLATELET RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	ZHOU Hongsheng Mohamed	Received

605-P	SHORT TERM RE-EXPOSURE TO ROMIPLOSTIM IN PREVIOUSLY TPO-MIMETIC RESPONSIVE ITP PATIENTS ALLOWS RECOVERY OF PLATELET COUNT AND LONG TERM SUSTAINED REMISSION: AN OBSERVATIONAL RETROSPECTIVE CASE-SERIES	Carpenedo Monica Brito	Received

606-P	THROMBOPOIETIN RECEPTOR AGONISTS IN PRIMARY IMMUNE THROMBOCYTOPENIA: EVALUATION OF EFFICACY (RESPONSE AND SUSTAINED RESPONSE OFF-TREATMENT) AND SAFETY IN A SINGLE CENTER POPULATION.	Santoro Cristina Mohamed	Received

607-P	PREDICTIVE FACTORS ASSOCIATED WITH LONG-TERM EFFECTS OF SPLENECTOMY FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA	Mitrovic Mirjana Mohamed	Received

608-P	THROMBOPOIETIN RECEPTOR AGONISTS AFFECTS THE LEVELS OF HEPATOCYTE GROWTH FACTOR AND TRANSFORMING GROWTH FACTORS IN IMMUNE THROMBOCYTOPENIA	GHANIMA Waleed Brito	Received

609-P	PREOPERATIVE USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN ITP PATIENTS PRIOR TO SPLENECTOMY OR CARDIOVASCULAR SURGERY.	De Stefano Valerio	Received

610-P	A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF 57 A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF 57 CONSECUTIVE LAPAROSCOPIC SPLENECTOMIES IN PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA	Novelli Silvana Ryun	Received

611-P	THE TREATMENT WITH ELTROMBOPAG OF THE REFRACTORY ITP	Gaman Mihnea-Alexandru Ryun	Received

612-P	THROMBOPOIETIC AGENTS INCREASE PLATELET COUNTS MORE EFFECTIVELY IN ITP PATIENTS WITH HIGHER PLATELET PRODUCTION PRIOR TO TREATMENT	Alexandra Kruse	Received

614-P	ROMIPLOSTIM: EFFICACY AND SAFETY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP). SINGLE CENTRE EXPERIENCE	Zotova Irina Ryun	Received

615-P	CORRELATION BETWEEN OXIDATIVE STRESS AND BIOMARKERS OF JOINT DAMAGE IN PATIENTS WITH SEVERE HAEMOPHILIA TREATED BY DIFFERENT PROPHYLAXIS REGIMENS	Djunic Irena Valerio	Received

616-P	BONE MINERAL DENSITY IN MEN AND CHILDREN WITH HAEMOPHILIA A AND B: A SYSTEMATIC REVIEW AND META-ANALYSIS	Anagnostis Panagiotis	Received

618-P	APPLICATION OF THE US NATIONAL INSTITUTE OF HEALTH (NIH) 2008 GUIDELINES FOR VON WILLEBRAND DISEASE IN A NATIONAL PAEDIATRIC COMPREHENSIVE CARE CENTRE.	Regan Irene Valerio	Received

620-P	MONITORING OF SUBSTITUTION THERAPY WITH RECOMBINANT FACTOR XIII OF A PATIENT WITH SEVERE FACTOR XIII A SUBUNIT DEFICIENCY	Muszbek László Valerio	Received

621-P	OPTIMAL MANAGEMENT OF A RARE COAGULATION DISORDER: FACTOR V DEFICIENCY	Elshinawy Mohamed Valerio	Received

622-P	THE CLINICOLABORATORY CHARACTERISTICS AND TREATMENT OUTCOMES OF 10 KOREAN PATIENTS WITH FACTOR V DEFICIENCY	Park Young Hoon	Received

623-P	DETECTION OF ANTI-THROMBOPOIETIN AUTOANTIBODY AMONG IMMUNE THROMBOCYTOPENIC PATIENTS	Miyazaki Koji Hoon	Received

624-P	HOMOZYGOUS PROTEIN C DEFICIENCY: A DESCRIPTION OF TWO NEW CASES AND LONG-TERM SURVIVAL OF A THIRD CASE SUCCESSFULLY TREATED WITH ORAL ANTICOAGULANT THERAPY, A REPORT FROM SAUDI ARABIA	Elborai Yasser Ryun	Received

625-P	AN AUDIT TO DETERMINE THE SAFETY OF THE NOVEL ORAL ANTICOAGULANTS, DABIGATRAN AND RIVAROXABAN, FOR PATIENTS INITIATED ON ANTICOAGULANT THERAPY	kurunadalingam Hariney Hoon	Received

626-P	COMPREHENSIVE SYMPTOM PROFILE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: PRACTICABILITY AND SENSITIVITY OF THE NEW SYMPTOM ASSESSMENT TOOL CSP LEUK-CML	Nikitina Tatiana Ryun	Received

628-P	THE VALUE OF DASATINIB THERAPY IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA FROM PHYSICIAN´S AND PATIENT´S PERSPECTIVE: "REAL WORLD" OUTCOMES	Nikitina Tatiana Ryun	Received

629-P	COVARIATION OF PSYCHOLOGICAL AND INFLAMMATORY VARIABLES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING IBRUTINIB	Maddocks Kami	Received

631-P	BONE MARROW ASPIRATION: A RANDOMIZED TRIAL ON THE QUALITY OF THE BONE MARROW SPECIMEN USING SLOW OR RAPID ASPIRATION TECHNIQUES AND ASSESSMENT OF THE PAIN INTENSITY	Jensen Paw Ryun	Received

632-P	IMPACT OF ANEMIA ON HEALTH-RELATED QUALITY-OF-LIFE AND CARDIAC REMODELING IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS). RESULTS OF GLOBQOL OBSERVATIONAL PROSPECTIVE STUDY.	RAMOS Fernando Hoon	Received

634-P	A FEASIBILITY STUDY OF VIRTUAL REALITY EXERCISE USING WII FIT AMONG PATIENTS WITH HEMATOLOGIC MALIGNANCIES RECEIVING CHEMOTHERAPY	Tsuda Kenji Ryun	Received

636-P	EDUCATIONAL INTERVENTION IN CANCER PATIENTS: THE IMPACT OF A CANCER SYMPOSIA ON PATIENT KNOWLEDGE	Padrnos Leslie Brito	Received

638-P	BURDEN OF ILLNESS OF PATIENS WITH CHRONIC LYMPHOCYTIC LEUKEMIA THAT ARE REFRACTORY TO FLUDARABINE AND ALEMTUZUMAB-CONTAINING REGIMENS IN SPAIN: AVERAGE COST ESTIMATION BY MONTECARLO SIMULATION	Parrondo García Javier	Received

640-P	PERSPECTIVE OF CHILDREN WITH CANCER ABOUT CANCER RELATED FATIGUE : A SINGLE CENTER EXPERIENCE	Hesham Mervat Ryun	Received

747-P	TARGETING THE DOPAMINE RECEPTOR SIGNALING REDUCES THE POLYCOMB PROTEIN BMI1 AND LIMITS THE SELF-RENEWAL OF BCR-ABL1 POSITIVE LEUKEMIA CELLS	Tauchi Tetsuzo Javier	Received

748-P	COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES	Iacobucci Ilaria Javier	Received

754-P	CD20 EXPRESSION IN ADULTS WITH PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) FROM UKALL14, ITS REGULATION BY DEXAMETHASONE AND RITUXIMAB INDUCED CYTOTOXICITY	Beaton Brendan Javier	Received

755-P	INHIBITION OF CLASS I PHOSPHATIDYLINOSITOL 3-KINASES (PI3KS) ISOFORMS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL): WHICH IS THE BEST THERAPEUTIC STRATEGY?	Lonetti Annalisa Javier	Received

757-P	"GENOMIC INVERSE PCR FOR EXPLORATION OF LIGATED BREAKPOINTS" (GIPFEL) - A NEW METHOD TO DETECT THE MOST COMMON TRANSLOCATIONS IN CHILDHOOD LEUKEMIA	Hoell Jessica Javier	Received

759-P	SIGNIFICANCE OF ADDITIONAL STRUCTURAL ABERRATIONS IN BONE MARROW CELLS OF 115 CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND HIGH HYPERDIPLOIDY	Lizcova Libuse Javier	Received

761-P	A COMPREHENSIVE NEW DNA TEST FOR DETECTION OF FUSION GENES IN LEUKEMIA	van den Berg-de	Received

766-P	6-MERCAPTOPURINE DOSAGE REDUCTION AND TPMT POLYMORPHISMS IN THE TREATMENT OF CHILDREN ACUTE LYMPHOBLASTIC LEUKEMIA	Ferreira Baptista Ana	Received

767-P	FREQUENCY AND CLINICAL SIGNIFICANCE OF OCCULT CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS	VILA-BOU Jordi Helena	Received

768-P	TREATMENT OF RELAPSED ACUTE LEUKEMIA AFTER ALLO-HSCT BY SALVAGE CHEMOTHERAPY WITH LOW-DOSE CYTARABINE AND ACLARUBICIN COMBINED WITH G-CSF PRIMING: MORE EFFECTIVE AND LESS TOXIC?	Wu Depei Ryun	Received

769-P	QUANTITATIVE ULTRASOUND OF PROXIMAL PHALANXES IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA SURVIVORS	De Matteo Antonia	Received

770-P	RELATIONSHIP BETWEEN MTHFR POLYMORPHISM AND SIDE EFFECTS OF HIGH-DOSE METHOTREXATE IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA	ragab Seham Ana	Received

772-P	MINIMAL RESIDUAL DISEASE IN ADULTS WITH PHILADELPHIA NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA - A SWEDISH POPULATION-BASED STUDY	Bergfelt Emma Ana	Received

773-P	INVASIVE FUNGAL INFECTIONS IN PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA: RESULTS FROM AN UNIVERSITY HOSPITAL, 2005 TO 2013	Sahbudak Bal Zümrüt	Received

774-P	ASPARAGINASE-ASSOCIATED PANCREATITIS (AAP) DURING TREATMENT FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)	Garrido Teresa Ana	Received

775-P	MOLECULAR CYTOGENETIC ANALYSIS IN 108 CHILDHOOD ACUTE LEUKEMIA PATIENTS FROM SAUDI ARABIA: CORRELATION TO MOLECULAR AND OTHER BIOLOGIC FACTORS	Elborai Yasser Antonia	Received

776-P	LENALIDOMIDE FOR TREATMENT OF REFRACTORY/RELAPSED ADULT B-ALL PATIENTS: RESULTS OF A MULTICENTRIC PHASE 2 STUDY.	Tavernier-Tardy Emmanuelle	Received

778-P	TRANSFUSION IRON INTAKE IN TRANSPLANT ELIGIBLE PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: RETROSPECTIVE ANALYSIS OF IRON LOAD AT THE END OF CHEMOTHERAPY PROGRAM AND BEFORE TRANSPLANTATION	Belotti Angelo Javier	Received

780-P	COPY NUMBER GAINS OF CHROMOSOME 1P36 LEAD TO PRDM16 OVEREXPRESSION IN AML PATIENTS	Baldazzi Carmen Ana	Received

781-P	CHARACTERIZATION OF THE RARE TRANSLOCATION T(3;10)(Q26;Q21) IN AN ACUTE MYELOID LEUKEMIA PATIENT	Jancušková Tereza Helena	Received

782-P	GSX2 DEREGULATION IN CD7+ ACUTE MYELOID LEUKEMIA BEARING 4Q12 TRANSLOCATIONS WITHOUT FUSION GENES	Di Giacomo Danika	Received

783-P	TELOMERE LENGTH IS SIGNIFICANTLY SHORTENED IN AML PATIENTS IN CYTOGENETIC REMISSION: POSSIBLE IMPLICATIONS ON THE ORIGIN OF AML	Ventura Ferreira Monica	Received

784-P	COMPLEX CHROMOSOMAL REARRANGEMENTS LEADING TO EVI1 OVEREXPRESSION ARE RECURRENT MECHANISMS IN CASES WITH VARIOUS 3Q ABNORMALITIES	Baldazzi Carmen Monica	Received

785-P	DEVELOPMENT OF MOLECULAR BEACON BASED PCR ASSAY FOR EASY DETECTION AND QUANTIFICATION OF CHIMERIC TRANSCRIPTS OF AML-ETO [T(8;21)] IN ACUTE MYELOID LEUKEMIA PATIENTS	Arora Rashi Monica	Received

786-P	ANALYSIS OF NPM1 SPLICE VARIANTS REVEALS DIFFERENTIAL EXPRESSION PATTERNS OF PROGNOSTIC VALUE IN ACUTE MYELOID LEUKEMIA	Zajac Malgorzata Monica	Received

787-P	HIGH LEVELS OF HOTAIRM1, A LONG INTERGENIC NON-CODING RNA RELATED TO HOX GENES, IS ASSOCIATED WITH POOR PROGNOSIS AND A DISTINCTIVE MICRORNA SIGNATURE IN INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA	diaz beya Marina	Received

788-P	CD123 (IL-3R?) IS CONSISTENTLY EXPRESSED ON ACUTE MYELOID LEUKEMIA (AML) CARRYING NUCLEOPHOSMIN (NPM1) GENE MUTATION	Brunetti Lorenzo Monica	Received

789-P	THE PROGNOSTIC VALUE OF LEUKEMIC STEM CELLS IN PEDIATRIC AML.	De Caluwé Bram	Received

790-P	BCL11B UP-REGULATION IN ACUTE MYELOID LEUKEMIA WITH CD2 T-ANTIGEN EXPRESSION AND FLT3 MUTATION	Brandimarte Lucia Monica	Received

791-P	PSEUDO-EXHAUSTION OF T CELLS IN RELAPSED AML	Lichtenegger Felix Monica	Received

794-P	NFATC1 MEDIATES SORAFENIB RESISTANCE IN FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA	Burchert Andreas Monica	Received

795-P	EXPRESSION OF FLT3-ITD DYSREGULATES THE DBC1-SIRT1-P53 SIGNALING AND PROMOTES THERAPY RESISTANCE	Sasca Daniel Monica	Received

798-P	PRE-CLINICAL ACTIVITY OF THE PI3K INHIBITOR BKM120 ON ACUTE MYELOID LEUKEMIA	Allegretti Matteo Monica	Received

799-P	THE CXCR4 ANTAGONIST BL-8040 SYNERGIZES WITH THE FLT3 INHIBITOR AC220 TO INDUCE APOPTOSIS AND REDUCE MINIMAL RESIDUAL DISEASE OF AML CELLS IN VIVO	Abraham Michal Monica	Received

804-P	A NOVEL CLEC12AXCD3 BISPECIFIC ANTIBODY EFFICIENTLY INDUCES T-CELL MEDIATED LYSIS OF CLEC12A+ AML BLASTS	Hangalapura Basav Bram	Received

805-P	CATHECHOLAMINES DIFFERENTLY REGULATE HUMAN AML AND NORMAL HEMATOPOIETIC PROGENITOR CELL MOTILITY VIA MIR126 AND RGS16	Avigdor Abraham Helena	Received

806-P	CELL-TO-CELL COMMUNICATION IN ACUTE MYELOID LEUKEMIA BY TUNNELING NANOTUBES	Omsland Maria Monica	Received

808-P	GLYCOLYSIS INHIBITION ON ACUTE MYELOID LEUKEMIA	Mirabilii Simone Monica	Received

810-P	THE ROS/SUMO AXIS IS INVOLVED IN ACUTE MYELOID LEUKEMIA (AML) CELLS RESPONSE TO CHEMOTHERAPEUTIC DRUGS AND CONSTITUTES A POTENTIAL TARGET TO OVERCOME CHEMORESISTANCE IN AML	bossis Guillaume Monica	Received

811-P	ARSENIC TRIOXIDE AND FUCOIDAN SYNERGIZE TO INDUCE APOPTOSIS IN ACUTE PROMYELOCYTIC LEUKEMIA	Atashrazm Farzaneh Monica	Received

812-P	THE PROGNOSTIC RELEVANCE OF THE 2008 WHO CLASSIFICATION OF MYELOID NEOPLASMS IN CHILDHOOD ACUTE MYELOID LEUKEMIA	Kinoshita Akitoshi Monica	Received

813-P	REVISITING THE CLONAL DYNAMICS OF TRISOMY 21 AND MONOSOMY 7 MOSAICISM IN CONGENITAL NEUTROPENIA AML	Ünalan Murat Zümrüt	Received

814-P	A SIMPLE AND EFFECTIVE STRATEGY TO DECREASE EARLY DEATHS IN ACUTE PROMYELOCYTIC LEUKEMIA USING A STREAMLINED SET OF GUIDELINES PAIRED WITH EXPERT SUPPORT.	kota Vamsi Monica	Received

815-P	INCIDENCE AND TYPE OF IDH1 AND IDH2 MUTATIONS IN AML-NK PATIENTS AND THEIR PROGNOSTIC IMPACT ON TREATMENT OUTCOME	Kim Yeo-Kyeoung Monica	Received

816-P	SCREENING OF TP53 (TUMOR PROTEIN 53) MUTATIONS IN ADULT ACUTE MYELOID LEUKEMIA (AML) PATIENTS REVEALS A STRONG ASSOCIATION WITH COMPLEX KARYOTYPE AND POOR OUTCOME	Ferrari Anna Bram	Received

822-P	VALIDATION OF SIE/SIES/GITMO "FITNESS CRITERIA" FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA: APPLICABILITY AND OUTCOME ANALYSIS ACCORDING TO FITNESS AND TO TREATMENT RECEIVED.	borlenghi Erika Monica	Received

823-P	C-KIT MUTATION IN CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA: PREVALENCE AND PROGNOSTIC ROLE IN TAIWAN. EXPERIENCE OF ONE SINGLE INSTITUTION	Lee Linkun Bram	Received

824-P	ADVERSE PROGNOSTIC IMPACT OF IDH MUTATIONS ON OUTCOME IN ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE	Virijevic Marijana Monica	Received

826-P	COMBINED USE OF MULTI-COLOR FCM AND PCR ANALYSIS CAN DETECT LESS THAN 0.01% PATHOLOGICAL CELLS IN THE VAST MAJORITY OF DE NOVO AML CASES	Kazuma Yasuhiro Monica	Received

827-P	INDOLEAMINE 2,3-DIOXYGENASE-1 (IDO-1) IS ASSOCIATED WITH HIGH INCIDENCE OF CHEMOREFRACTORY DISEASE IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS	Parisi Sarah Monica	Received

829-P	INTEREST OF CYTOGENETIC AND FISH EVALUATION FOR PROGNOSIS EVALUATION IN 198 PATIENTS WITH ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION IN A SINGLE INSTITUTION	Hirsch Pierre Monica	Received

830-P	ACUTE MYELOID LEUKEMIA IN PATIENTS OLDER THAN 75: PROGNOSTIC IMPACT OF FLT3-ITD AND NPM1 MUTATIONS	Hirsch Pierre Monica	Received

831-P	MOLECULAR RELEVANCE OF THE NERVE GROWTH FACTOR RECEPTOR GENE (NTRK1) EXPRESSION IN AML-RELATED MYELOID SARCOMA	lazzaroni Francesca Bram	Received

832-P	ELN FAVORABLE ACUTE MYELOID LEUKEMIA SHARE THE SAME GOOD PROGNOSIS ACROSS CYTOGENETIC/MOLECULAR SUBGROUPS: PRELIMINARY RETROSPECTIVE REAL-LIFE ANALYSIS OF THE RETE EMATOLOGICA LOMBARDA (REL)	Zappasodi Patrizia Monica	Received

833-P	A POST-REMISSION MAINTENANCE TREATMENT WITH LOW-DOSE CHEMOTHERAPY + RETINOIDS AND DIHYDROXYLATED VITAMIN D3 MAY IMPROVE THE SURVIVAL OF POOR-PROGNOSIS AML/MDS PATIENTS	Ferrero Dario Monica	Received

834-P	MDRO INFECTION THE ´´MAJOR HURDLE TO ACUTE MYELOID LEUKEMIA INDUCTION THERAPY" EXPERIENCE OF A TERTIARY CARE COMPREHENSIVE CANCER CENTER FROM INDIA.	CHAKRAPANI Anupam Bram	Received

835-P	ACQUIRED IDH1 AND IDH2 MUTATIONS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKAEMIA: THEIR PREVALENCE AND ASSOCIATION WITH OTHER GENE MUTATIONS – A SINGLE CENTRE EXPERIENCE	How Gee Fung	Received

841-P	NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS CAN BENEFIT FROM A SIGNIFICANT BETTER SURVIVAL WHEN INCLUDED IN CLINICAL TRIALS	MICHALLET Mauricette Fung	Received

843-P	COMPARATIVE ANALYSIS OF FOUR COURSES OF STANDARD-DOSE CONSOLIDATION WITHOUT MAINTENANCE VERSUS THREE COURSES OF LOW-INTENSITY CONSOLIDATION WITH MAINTENANCE IN ADULTS WITH ACUTE MIELOID LEUKEMIA	SEMOCHKIN Sergey Fung	Received

844-P	MN1 OVEREXPRESSION IS A POWERFUL PREDICTOR OF FAILURE OF INDUCTION CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIAS SUCH AS CONVENTIONAL CYTOGENETICS AND AGE.	Rodríguez Carlos Fung	Received

846-P	TARGETED ARRAYCGH USED FOR DETERMINING MINIMALLY DELETED REGION ON CHROMOSOME 6Q IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS	Jarosova Marie Bram	Received

848-P	NOD/SCID GAMMA XENOGRAFT MODEL OF B-CELL MALIGNANCIES USING TP53- AND/OR ATM-DEFICIENT CELL LINES	Verner Jan Fung	Received

849-P	COPY NUMBER ALTERATIONS AND NOTCH1 MUTATIONS PREDICT THE OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA AND NORMAL FISH	Delgado Julio Bram	Received

851-P	TAP63 IS EPIGENETICALLY REGULATED AND HIGHLY OVEREXPRESSED IN AGGRESSIVE CLL STEREOTYPED SUBSET #8	Stamatopoulos Kostas Fung	Received

853-P	CYTOGENETIC EVOLUTION PATTERNS IN CHRONIC LYMPHOCYTIC LEUKEMIA	Iskas Michail Bram	Received

854-P	CHARACTERIZATION AND SIGNIFICANCE OF RARE BALANCED IMMUNOGLOBULIN TRANSLOCATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA	Van Obbergh Florence	Received

855-P	IMPACT OF TWO CYTOGENETIC LESIONS ON THE OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Visentin Andrea Florence	Received

856-P	SF3B1 MUTATIONS IN CLL ARE ASSOCIATED WITH A DEFECTIVE DNA DAMAGE RESPONSE	Eldering Eric Fung	Received

857-P	SYSTEMATIC DRUG SENSITIVITY SCREENING IN LYMPHOID MALIGNANCIES IDENTIFIES VULNERABILITIES OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH HIGH RISK ABERRATIONS	Sellner Leopold Fung	Received

858-P	TRISOMY 12 IS ASSOCIATED WITH A DISTINCT PATTERN OF LYMPHOCYTOSIS DURING TREATMENT OF CLL WITH IBRUTINIB, WHICH DOES NOT AFFECT RESPONSE DEPTH OR DURATION	Thompson Philip Fung	Received

859-P	INTEGRATION OF NOVEL GENE MUTATIONS INTO KARYOTYPE-BASED SUBGROUPS AS A PROGNOSTIC RISK STRATIFICATION TOOL IN CHRONIC LYMPHOCYTIC LEUKEMIA	Del Giudice Ilaria	Received

862-P	ITALIAN VALIDATION OF THE MDACC PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: ANALYSIS OF 1502 CASES.	Gentile Massimo Helena	Received

864-P	SKIN CANCERS ARE COMMON AND CAUSE CONSIDERABLE MORBIDITY IN PATIENTS TREATED WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB FOR CHRONIC LYMPHOCYTIC LEUKAEMIA	Tam Constantine Florence	Received

865-P	A POPULATION BASED EXPERIENCE ON THE USE OF RCD OR RCVP IN AUTOIMMUNE HEMOLYTIC ANEMIA IN CLL	Kumar Rajat Florence	Received

869-P	OPEN LABEL MULTICENTER STUDY OF ELTROMBOPAG FOR THE TREATMENT OF IMMUNE THROMBOCYTOPENIA SECONDARY TO LYMPHOPROLIFERATIVE DISORDERS	Visco Carlo Florence	Received

870-P	IS ZAP-70 STILL A KEY PROGNOSTIC FACTOR IN EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA? RESULTS OF THE ANALYSIS FROM A PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY	Gentile Massimo Ilaria	Received

871-P	EVALUATION OF IMMUNE RESPONSE TO 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE (PCV13) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA	Rolinski Jacek Florence	Received

872-P	INITIAL CHARACTERISTICS, TREATMENT AND PROGNOSIS ACCORDING TO AGE IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A SINGLE-CENTER ANALYSIS BASED ON 949 PATIENTS.	Baumann Tycho Florence	Received

873-P	IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA A HIGH NUMBER OF CELLS WITH TRISOMY 12 IS ASSOCIATED WITH A POOR OUTCOME. ANALYSIS OF DATABASE OF SPANISH GROUPS OF CYTOGENETICS (GCECGH) AND CLL (GELLC)	José-Ángel Hernández Florence	Received

874-P	COMPARATIVE EFFECT OF BENDAMUSTINE PLUS RITUXIMAB (R) VS FLUDARABINE PLUS CYCLOPHOSPHAMIDE PLUS R ON THE LEVELS OF PERIPHERAL BLOOD LEUCOCYTE POPULATIONS IN ADVANCED-STAGE CHRONIC LYMPHOCYTIC LEUKEMIA	Barrena Susana	Received

877-P	ANALYSIS OF MERKEL CELL POLYOMAVIRUS PROGNOSTIC SIGNIFICANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA	Doubek Michael Romana	Received

878-P	A PATHOLOGICAL ABDOMINAL ULTRASONOGRAPHY AT DIAGNOSIS OF CLL SIGNIFICANTLY REDUCES THE TIME TO PROGRESSION IN PATIENTS WITH RAI 0 OR 1 DISEASE	Rossini Fausto Zümrüt	Received

879-P	IN VITRO COMPARATIVE STUDY ON DIRECT KILLING OF CLL CELLS BY SMALL TARGETED THERAPEUTIC MOLECULES	Eketorp Sylvan	Received

881-P	DO CHRONIC MYELOID LEUKEMIA PATIENTS WITH LATE "WARNING" RESPONSES BENEFIT FROM SWITCHING THERAPY TO A SECOND GENERATION TYROSINE KINASE INHIBITOR?	García-Gutiérrez Valentin Ilaria	Received

885-P	DASATINIB PHARMACOKINETICS AND ITS CORRELATION WITH CLINICAL RESPONSE IN CHRONIC MYELOID LEUKEMIA: A SUBANALYSIS OF THE DARIA-01 STUDY	Miyao Kotaro Ilaria	Received

888-P	LONG-TERM RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL OF HIGH-DOSE IMATINIB WITH OR WITHOUT INTERFERON-? IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE	Koji Sasaki	Received

897-P	OUTCOMES OF THIRD-LINE BCR-ABL1 TYROSINE KINASE INHIBITORS IN THE TREATMENT FAILED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WHO HAVE RECEIVED TWO PRIOR TKIS	Lee Sung-Eun Sandra	Received

898-P	PREDICTIVE FACTORS FOR OUTCOME TO NOVEL BCR-ABL1 TYROSINE KINASE INHIBITORS IN IMATINIB FAILED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA	Lee Sung-Eun Sandra	Received

899-P	OUTCOMES OF PREGNANCY AND THERAPEUTIC APPROACHES IN CHRONIC MYELOID LEUKEMIA DURING PREGNANCY	Chelysheva Ekaterina Monica	Received

901-P	CHROMOSOMAL ABNORMALITIES IN PHILADELPHIA CHROMOSOME (PH)-NEGATIVE METAPHASES IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE TREATED FRONTLINE WITH NILOTINIB OR DASATINIB	Shah Shilpan Ilaria	Received

902-P	CLINICAL EXPERIENCE OF BOSUTINIB UNDER COMPASIONATE USE PROGRAM IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH RESISTANCE OR INTOLERANCE TO IMATINIB, DASATINIB AND NILOTINIB	García-Gutiérrez Valentin Ilaria	Received

904-P	DESIGN OF RAPID FLUORESCENT MOLECULAR BEACON BASED PCR ASSAY FOR DETECTION AND QUANTIFICATION OF BCR –ABL TRANSCRIPTS IN CHRONIC MYELOID LEUKEMIA PATIENTS	Jetly Sunita Ilaria	Received

905-P	HYPOPHOSPHATEMIA AS A PREDICTOR OF RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML) TREATED WITH IMATINIB	Garrido Teresa Ilaria	Received

906-P	RISK AND IMPACT OF TUBERCULOSIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A NATIONWIDE POPULATION-BASED STUDY IN TAIWAN	Liu Chia-Jen Ilaria	Received

907-P	MULTICENTER CLINICAL STUDY TO EVALUATE A UTILITY OF FRET-BASED DRUG SENRITIVITY TEST THAT PREDICTS EARLY MOLECULAR RESPONSE IN NEWLY DIAGNOSED CML PATIENTS TREATED WITH NILOTINIB	Kondo Takeshi Monica	Received

908-P	FIRST PRELIMINARY REPORT OF ARAB LEUKEMIA NET (ALN) REGISTRY FOR CHRONIC MYELOID LEUKAEMIA (CML) IN THE MIDDLE EAST &NORTH AFRICA REGION.PART I EPIDEMIOLOGY OF CML IN EGYPT.	AZZAZI Mohamed Ilaria	Received

913-P	THE EFFECT OF DELAYED TKI TREATMENT ON CYTOGENETIC AND MOLECULAR RESPONSES: 8 YEAR FOLLOW-UP STUDY IN BOSNIA	KURTOVIC Azra Sandra	Received

914-P	THE TYROSINE KINASE INHIBITOR AXITINIB TARGETS T315I-MUTANT BCR-ABL DRIVEN LEUKEMIAS IN VITRO AND IN VIVO	Pemovska Tea Ilaria	Received

916-P	THE INFLUENCE OF DISEASE AND COMORBIDITY RISK ASSESSMENTS ON THE SURVIVAL OF MDS PATIENTS TREATED WITH 5-AZACITIDINE	molteni Alfredo Sandra	Received

917-P	IRON-CHELATING THERAPY WITH DEFERASIROX IN HIGHER RISK MYELODYSPLASTIC SYNDROMES: A RETROSPECTIVE, MULTICENTER, ITALIAN STUDY	Musto Pellegrino Ilaria	Received

918-P	MYELODYSPLASTIC SYNDROMES: AN INTEGRATED MOLECULAR/CYTOGENETIC WORKUP FOR A CORRECT PATIENTS´ RISK STRATIFICATION.	GALIMBERTI Sara Ilaria	Received

920-P	HIGHER BONE MARROW LGALS3 EXPRESSION PREDICTS FAVORABLE PROGNOSIS IN ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROME	Hou Hsin-An Ilaria	Received

921-P	VALUE OF THE MULTIPARAMETRIC FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA UNDER HYPOMETHYLATING AGENT THERAPY.	iastrebner Marcelo Sandra	Received

922-P	CLINICAL VALUE OF MONOSOMAL KARYOTYPE AND COMPLEX KARYOTYPE AS PROGNOSTIC PARAMETER IN PATIENTS WITH IPSS INTERMEDIATE-2 AND HIGH RISK MYELODYSPLASTIC SYNDROMES TREATED WITH AZACITIDINE	song Moo Kon	Received

924-P	A PHASE II STUDY EXPLORING THE FEASIBILITY OF AZACITIDINE AND LENALIDOMIDE USE (COMBINATION VS SEQUENTIAL TREATMENT) FOR HIGHER-RISK MYELODYSPLASTIC SYNDROMES (IPSS RISK: HIGH OR INT-2)	Finelli Carlo Kon	Received

925-P	IMPACT OF GRAFT-VERSUS-HOST DISEASE ON OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR LOW-RISK MYELODYSPLASTIC SYNDROMES	Aoki Jun Kon	Received

926-P	IMPACT OF TP53 MUTATION ON OUTCOME OF MDS PATIENTS UNDERGOING ALLOGENEIC TRASPLANT	Díez Campelo María	Received

927-P	ISOCHROMOSOME 17Q10 IN MYELOID NEOPLASMS IS FREQUENTLY ASSOCIATED WITH MULTIPLE MUTATIONS AND TRANSFORMATION TO ACUTE MEGAKARYOBLASTIC LEUKEMIA	ZHOU Hongsheng María	Received

929-P	IMPACT OF HIGH-DOSE RADIATION EXPOSURE ON NAGASAKI ATOMIC BOMB SURVIVORS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH AZACITIDINE	Jo Tatsuro María	Received

930-P	TREG CELLS NUMBER FROM HIGH-RISK MYELODISPLASTIC SYNDROME PATIENTS IS INCREASE, BUT ITS SUPRESSION HABILITY IS IMPARED	PERAZZIO Aline María	Received

931-P	METHYLATION PATTERNS IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SINDROMES AND SECONDARY ACUTE MYELOID LEUKEMIA TREATED WITH HIPOMETHYLANT AGENTS (HIGH-RISK MDS 2009 PROTOCOL OF CETLAM GROUP).	Cabezón Marta Monica	Received

932-P	HIF-1? INHIBITION BLOCKS THE CROSS TALK BETWEEN MULTIPLE MYELOMA PLASMA CELLS AND TUMOR MICROENVIRONMENT	Borsi Enrica Kon	Received

936-P	PROTEASOME INHIBITORS MODULATE OSTEOCYTE DEATH AND AUTOPHAGY IN MULTIPLE MYELOMA.	Giuliani Nicola María	Received

937-P	THE METABOLIC STRESS INDUCED BY CYCLIN D1 IMPACTS CELL ADHESION, MIGRATION AND CELL ADHESION-MEDIATED DRUG RESISTANCE (CAM-DR) IN MYELOMA CELLS.	Bustany Sophie Monica	Received

938-P	CYCLIN D1 CONSTITUTIVE EXPRESSION SENSITIZES MULTIPLE MYELOMA CELLS TO BORTEZOMIB BY INHIBITING HEAT SHOCK PROTEINS.	Bustany Sophie Monica	Received

939-P	SERUM LEVELS OF DICKKOPF-1 PREDICT PROGRESSION FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS TREATED WITH AUTOLOGOUS STEM CELL TRANSPLANTAT BUT ITS PROGNOSTIC VALUE IS OVERCOME BY THE USE OF NOVEL DRUGS	Minarik Jiri Kon	Received

940-P	IMPACT OF EXONIZED ALUS ON SOLUBLE RANKL MRNA TRANSLATIONAL DYNAMICS.	Papamichos Spyros Kon	Received

941-P	FIBROBLAST ACTIVATION PROTEIN PROTECTS BORTEZOMIB INDUCED APOPTOSIS IN MULTIPLE MYELOMA CELLS THROUGH ?-CATENIN SIGNALING PATHWAY	Cai Zhen Kon	Received

942-P	PRECLINICAL ANTIMYELOMA ACTIVITY OF THE ALKYLATING-HDACI FUSION MOLECULE EDO-S101 THROUGH DNA-DAMAGING AND HDACI EFFECTS	López-Iglesias Ana Alicia	Received

943-P	SAR650984, A HUMANIZED ANTI-CD38 ANTIBODY, POTENTLY TARGETS CANCER CELLS THROUGH MULTIPLE MECHANISMS	Cai Ti Monica	Received

944-P	NETWORK OF MICRO RNA AND EPIGENETICS ARE ASSOCIATED WITH THE PROGRESSION OF MGUS AND MULTIPLE MYELOMA.	Handa Hiroshi Alicia	Received

945-P	CHARACTERIZATION OF SERUM AND GLUCOCORTICOID-INDUCIBLE KINASE 3 (SGK-3) AS A POTENTIAL ONCOGENIC ALTERNATIVE TO SIGNALLING VIA AKT IN MULTIPLE MYELOMA	Seggewiss-Bernhardt Ruth Alicia	Received

946-P	ORAL STATIN USE ASSOCIATED WITH REDUCED RISK OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND MULTIPLE MYELOMA: A POPULATION BASED NESTED CASE-CONTROL STUDY	McShane Charlene Alicia	Received

948-P	IMMUNE IMPAIRMENTS IN MULTIPLE MYELOMA BONE-MARROW MESENCHYMAL STROMAL CELLS	André Thibaud Kon	Received

950-P	PREVALENCE AND PROGNOSIS SIGNIFICANCE OF THE MYD88 (L265P) MUTATION IN IGM MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND SMOLDERING WALDENSTRÖM MACROGLOBULINEMIA	Fernández de	Received

951-P	INHIBITION OF NAMPT AUGMENTS IBRUTINIB INDUCED KILLING IN MYD88 L265P EXPRESSING WALDENSTROM`S MACROGLOBULINEMIA CELLS.	Cagnetta Antonia de	Received

954-P	COMPARISON OF THE N-LATEX AND FREELITE ASSAYS FOR SERUM FREE LIGHT CHAIN: CLINICAL PERFORMANCE IN AL AMYLOIDOSIS	Palladini Giovanni de	Received

955-P	CYSTATIN C BASED ESTIMATION OF GLOMERULAR FILTRATION RATE IN AL AMYLOIDOSIS	Milani Paolo de	Received

956-P	A PROFILE OF 140 LONG-TERM SURVIVORS WITH SYSTEMIC AL AMYLOIDOSIS	Sachchithanantham Sajitha de	Received

961-P	BENDAMUSTINE AND PREDNISONE IN COMBINATION WITH BORTEZOMIB (BPV) IN THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED/UNTREATED MULTIPLE MYELOMA.	Poenisch Wolfram de	Received

962-P	WHOLE-BODY LOW-DOSE CT (WBLDCT) IS USEFUL FOR DETECTION, STAGING, RESPONSE EVALUATION AND FOLLOW-UP IN MYELOMA PATIENTS	Rossini Fausto de	Received

963-P	PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE (VPD) AS INDUCTION THERAPY IN PATIENTS WITH MULTIPLE MYELOMA CANDIDATES TO AUTOLOGOUS TRANSPLANT	mangiacavalli Silvia Kon	Received

969-P	IMPACT OF CONSOLIDATION WITH BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE (VTD) UPFRONT IN MULTIPLE MYELOMA (MM) WITH PARTIAL RESPONSE (PR) AT COMPLETION OF INDUCTION WITH VTD	Leleu Xavier Kon	Received

975-P	LONG TERM CRYOPRESERVED AUTOLOGOUS BLOOD STEM CELLS FOR SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELAPSED MULTIPLE MYELOMA PATIENTS	Areethamsirikul Nuchanan Kon	Received

976-P	MULTIPLE MYELOMA OF ELDERLY: COMORBIDITY INDEXES, SCALES, AND PERSONALIZED TREATMENT	Djurasinovic Vladislava Monica	Received

977-P	SMOULDERING MULTIPLE MYELOMA RISK FACTORS FOR PROGRESSION. AN ANALYSIS OF 289 CASES IN THE DANISH MULTIPLE MYELOMA REGISTRY	Sørrig Rasmus Monica	Received

983-P	A COMBINATION THERAPY WITH BORTEZOMIB (BOR) AND THALIDOMIDE IN NEWLY DIAGNOSED MYELOMA PATIENTS IS ASSOCIATED WITH A LOW INCIDENCE OF SECOND PRIMARY MALIGNANCIES (SPMS)	Brioli Annamaria de	Received

984-P	DIFFERENT OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION ACCORDING TO INVOLVED SITES IN MYELOMA PATIENTS WITH EXTRAMEDULLARY PLASMACYTOMA: BONE VERSUS SOFT TISSUE PLASMACYTOMA	Shin Ho-Jin Kon	Received

985-P	EARLY MORTALITY TREND IN MULTIPLE MYELOMA: A THIRTY-YEAR POPULATION-BASED STUDY	Ríos-Tamayo Rafael de	Received

988-P	AN ONGOING OPEN-LABEL PHASE 1/2A STUDY OF THE SAFETY AND EFFICACY OF MELFLUFEN AND DEXAMETHASONE COMBINATION FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)	Nordström Eva Kon	Received

990-P	ROLE OF IMMUNOHISTOCHEMISTRY IN THE DIAGNOSIS OF SYSTEMIC IMMUNOGLOBULIN LIGHT-CHAIN AMYLOIDOSIS: RESULTS IN A SERIES FROM A SINGLE INSTITUTION	Fernández de	Received

992-P	IMPACT OF INITIAL FGD-PET CT AND SERUM FREE LIGHT CHAIN ON TRANSFORMATION OF CONVENTIONALLY DEFINED SOLITARY PLASMACYTOMA TO MULTIPLE MYELOMA	FOUQUET Guillemette de	Received

993-P	NEGATIVE FLOW CYTOMETRY IS ASSOCIATED WITH A BETTER PROGRESSION-FREE SURVIVAL IN TREATED MULTIPLE MYELOMA PATIENTS: THE SINGLE-CENTER EXPERIENCE OF CHU DE CAEN IN A DAILY PRACTICE	Cabrera Quentin de	Received

994-P	HIGH INCIDENCE OF INTACT IMMUNOGLOBULIN OR FRAGMENTS THEREOF IN URINE OF PATIENTS WITH MULTIPLE MYELOMA	Kraj Maria de	Received

995-P	VALIDATION OF THE SPECIFIC HEMATOPOIETIC-CELL-TRANSPLANTATION COMORBIDITY INDEX IN PATIENTS WITH MULTIPLE MYELOMA	Jelicic Jelena de	Received

996-P	RELATIONSHIP BETWEEN CHROMOSOMAL ABERRATIONS AND CLINICAL OR LABORATORY VARIABLES IN MULTIPLE MYELOMA	Wawrzyniak Ewa de	Received

1000-P	NUTRITIONAL COUNSELING IN SYSTEMIC IMMUNOGLOBULIN LIGHT-CHAIN (AL) AMYLOIDOSIS: A PROSPECTIVE RANDOMIZED, CONTROLLED TRIAL	Palladini Giovanni	Received

1002-P	BONE MARROW ASPIRATION SIGNIFICANTLY UNDERESTIMATES THE BURDEN OF DISEASE IN MULTIPLE MYELOMA AT DIAGNOSIS AND FOLLOW UP COMPARED WITH THE BONE MARROW TREPHINE	Thomas Alison	Received

1004-P	IMPACT OF NF?B1-94INS/DEL ATTG POLYMORPHISM ON DISEASE CHARACTERISTICS AND TREATMENT OUTCOME ON BORTEZOMIB BASED THERAPY IN PATIENTS WITH MULTIPLE MYELOMA	Varga Gergely	Received

1005-P	THIRD AUTOLOGOUS SALVAGE STEM CELL TRANSPLANT IN SUBJECTS WITH ADVANCED MULTIPLE MYELOMA	Strifler Susanne	Received

1006-P	TREATMENT WITH THE BILE-ACID SEQUESTRANT COLESEVELAM IMPROVES LENALIDOMIDE ASSOCIATED DIARRHOEA IN MYELOMA PATIENTS.	PAWLYN Charlotte	Received

1007-P	PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB	Mian Michael	Received

1009-P	EVALUATION OF VAD PROTOCOL IN MULTIPLE MYELOMA OVER A PERIOD OF 10 YEARS	hanan Moussaoui	Received

1010-P	A SIMPLE METHOD TO DETECT COPY NUMBER-NEUTRAL 6P-LOH IN PATIENTS WITH ACQUIRED APLASTIC ANEMIA USING DUPLEX QUANTITATIVE PCR	Zaimoku Yoshitaka	Received

1011-P	EPIGENETIC ALTERATIONS IN FANCONI ANAEMIA: ROLE IN DISEASE PROGRESSION AND THERAPEUTIC POTENTIAL	Belo Hélio	Received

1012-P	CHRONIC IDIOPATHIC NEUTROPENIA DOES NOT DISPLAY FREQUENT STAT3 MUTATIONS: IMPLICATIONS FOR DIFFERENTIAL DIAGNOSIS FROM OTHER CLINICAL SYNDROMES WITH T-CELL-MEDIATED SUPPRESSION OF HEMATOPOIESIS	Stalika Evangelia	Received

1014-P	PARAMETERS OF CELL IMMUNITY IN PATIENTS WITH APLASTIC ANEMIA AND THEIR RELATION TO PNH-CLONE	Rozanova Olga	Received

1015-P	ABNORMAL METABOLITES RELATED TO BONE MARROW FAILURE IN APLASTIC ANEMIA PATIENTS	xing Cui	Received

1016-P	PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: CLINICAL EXPRESSION AND RESPONSE TO TREATMENT ARE MODIFIED BY A UNIQUE INTERACTION WITH CO-EXISTING GLUCOSE 6-PHOSPHATE DEHYDROGENASE DEFICIENCY	Notaro Rosario	Received

1020-P	INCREASED BONE MARROW (BM) PLASMA LEVELS OF SOLUBLE CD30 CORRELATE WITH BM PLASMA LEVELS OF INTERFERON (IFN)-GAMMA, CD4/CD8 T-CELL RATIO AND DISEASE SEVERITY IN APLASTIC ANEMIA	zhang Jizhou	Received

1021-P	EVALUATION OF GENETIC TESTING FOR FANCONI ANAEMIA: FROM SANGER TO NEXT GENERATION SEQUENCE ANALYSIS	Goodeve Anne	Received

1022-P	DIAMOND-BLACKFAN ANEMIA IN RUSSIAN FEDERATION	Smetanina Nataliya	Received

1023-P	TELOMERASE ENZYME ACTIVITY IN EGYPTIAN CHILDREN WITH E ANDBONE MARROW FAILUR RESPONSE TO IMMUNESUPRESSIVE THERAPY	Elbeshlawy Amal	Received

1028-P	PKC412 (MIDOSTAURIN) IS SAFE AND HIGHLY EFFECTIVE IN SYSTEMIC MASTOCYTOSIS PATIENTS: FOLLOW UP OF A SINGLE-CENTER ITALIAN COMPASSIONATE USE	Papayannidis Cristina	Received

1029-P	DIAGNOSTIC ACCURACY OF SERUM EPO LEVEL AND JAK2V617F ALLELE BURDEN IN POLYCYTHEMIA VERA	Ancochea Agueda	Received

1030-P	CALR MUTATIONS IN ESSENTIAL THROMBOCYTHEMIA: INCIDENCE, CLINICAL UTILITY AND MOLECULAR DIAGNOSTIC BY HIGH RESOLUTION MELTING	GOMEZ CASARES Maria	Received

1032-P	YOUNG AGE IS NOT PROTECTIVE AGAINST THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA	Randi Maria Luigia	Received

1035-P	A PROGNOSTIC MODEL TO PREDICT THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA	Lekovic Danijela Luigia	Received

1036-P	CLINICAL FEATURES OF PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA DIAGNOSED BETWEEN THE AGES OF 41-59YEARS IN COMPARISON TO PATIENTS DIAGNOSED AT OR BELOW THE AGE OF 40	Kam Grace	Received

1037-P	CARDIOVASCULAR EVENTS: RISK FACTORS AND CORRELATIONS WITH THE JAK2V617F ALLELE BURDEN IN PATIENTS WITH PH´-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS. A MONOCENTRIC STUDY.	FONTANELLI Giulia Maria	Received

1038-P	BACK TO LIFE -LIVING, TREATING, MANAGING MYELOFIBROSIS: THE BURDEN OF ILLNESS FOR PATIENTS AND THEIR FAMILIES	Marini Maria Giulia	Received

1039-P	GENDER DIFFERENCES AND MPN SYMPTOM BURDEN: AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG)	Geyer Holly Giulia	Received

1040-P	OUTCOME OF PATIENTS AGED OVER 60 WITH CLASSICAL HODGKIN LYMPHOMA TREATED WITH ABVD	Stamatoullas Aspasia Giulia	Received

1041-P	EVALUATION OF THE PROGNOSTIC ROLE OF TISSUE ASSOCIATED MACROPHAGES (TAM) IN HODGKIN LYMPHOMA AND CORRELATION WITH EARLY FDG-PET ASSESSMENT.	Fabbri Alberto	Received

1045-P	PET-ADAPTED TREATMENT MODIFICATION IN EARLY STAGE HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS	Sickinger Marie Therese	Received

1049-P	ABVD IN TREATMENT OF GENERATIVE AGE FEMALES WITH ADVANCED HODGKIN LYMPHOMA – A RISK FACTOR ANALYSIS	Andjelic Bosko Luigia	Received

1052-P	PRELIMINARY RESULTS OF THE TREATMENT OF PATIENTS WITH HODGKIN´S DISEASE FROM INTERMEDIATE RISK GROUP	Kriachok Iryna Luigia	Received

1055-P	POST-TREATMENT RESIDUAL MASSES DETECTED BY COMPUTED TOMOGRAPHY SCAN SIGNIFICANTLY AFFECT THE CLINICAL OUTCOME OF HODGKIN LYMPHOMA PATIENTS WITH NEGATIVE POSITRON EMISSION TOMOGRAPHY SCAN.	Magagnoli Massimo Therese	Received

1056-P	MYC ONCOGENE IS OVEREXPRESSED IN HODGKIN & REED STERNBERG CELLS (HRS) OF CLASSICAL HODGKIN LYMPHOMA AND CORRELATES WITH P53 EXPRESSION AND PROLIFERATION INDEX	RASSIDAKIS George Maria	Received

1058-P	PNEUMOCYSTIS CARINII PNEUMONIA IN PATIENTS WITH HODGKIN´S LYMPHOMA	Julhakyan Hunan Therese	Received

1060-P	IMPAIRED RHOA FUNCTION LEADS TO DEVELOPMENT OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA	Enami Terukazu Therese	Received

1063-P	EXPRESSION PATTERN AND FUNCTIONAL ROLE OF TOLL-LIKE RECEPTORS IN SPLENIC MARGINAL ZONE LYMPHOMA	Fonte Eleonora Luigia	Received

1064-P	DROPLET DIGITAL PCR (DDPCR) AND REAL-TIME PCR (RQ-PCR): A HEAD TO HEAD COMPARISON FOR MRD DETECTION IN MYELOMA (MM) MANTLE CELL LYMPHOMA (MCL) AND FOLLICULAR LYMPHOMA (FL)	drandi Daniela Luigia	Received

1066-P	HIGH-THROUGHPUT ANALYSIS OF FULL-LENGTH IMMUNOGLOBULIN TRANSCRIPTS BY TEMPLATE-SWITCHING ANCHORED PCR AND MASSIVE PARALLEL SEQUENCING ON THE PACBIO PLATFORM	Koning Marvyn Luigia	Received

1068-P	GERMLINE SMALL NON CODING RNAS, PIWIRNAS, ARE EXPRESSED IN HODGKIN LYMPHOMA: THE ROLE OF PIWIRNA-651 AS PROGNOSTIC FACTOR IN HODGKIN LYMPHOMA.	Navarro Alfons Therese	Received

1069-P	ISOLD: A VALUABLE SCORE TO DISCRIMINATE OCULAR LYMPHOMA FROM INFLAMMATORY DISEASES	Costopoulos Myrto Luigia	Received

1070-P	GENOME-WIDE DNA METHYLATION ANALYSIS REVEALS ACTIVATION OF WNT SIGNALING PATHWAY IN PERIPHERAL T-CELL LYMPHOMA-NOT OTHERWISE SPECIFIED	Zhao Xia Roberta	Received

1072-P	BACH2 SUPPRESSION IN CD4+ T CELLS MODULATES THEIR RESISTANCE TO APOPTOSIS DEMONSTRATING ITS FUNCTION AS A TUMOR SUPPRESSOR GENE	Dang Chi Vu	Received

1073-P	SUBMICROSCOPIC GENOMIC REARRANGEMENTS CHANGE GENE EXPRESSION IN T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA	Izykowska Katarzyna Therese	Received

1077-P	MIR-150 REGULATES IL-22-CCL20-CCR6 AUTOCRINE PATHWAY IN METASTATIC CUTANEOUS T- CELL LYMPHOMA	Teshima Kazuaki Vu	Received

1078-P	IN VITRO AND IN VIVO EFFECT OF ATO/IFN/AZT FOR ADULT T CELL LEUKEMIA/LYMPHOMA	Yoshimitsu Makoto Vu	Received

1081-P	BONE MARROW INVOLVEMENT AT DIAGNOSIS IS A POOR PROGNOSTIC FACTOR IN YOUNG PATIENTS WITH UNTREATED HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: SUB-ANALYSIS OF THE PHASE III RANDOMIZED FIL-DLCL04 TRIAL	Chiappella Annalisa Vu	Received

1082-P	VITAMIN D DEFICIENCY (VDD) IMPAIRS RITUXIMAB-MEDIATED CELLULAR CYTOTOXICITY AND OUTCOME OF DLBCL PATIENTS TREATED WITH, BUT NOT WITHOUT RITUXIMAB (R)	Pfreundschuh Michael Vu	Received

1083-P	COMBINING SEVERAL MOLECULAR ABNORMALITIES IN IDENTIFICATION OF HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA IMPROVES RISK-STRATIFICATION	Fiskvik Idun Therese	Received

1084-P	DEFINING ACCURACY AND SENSITIVITY OF T-CELL RECEPTOR REPERTOIRE PROFILING FOR MONITORING RECURRENT/PERSISTENT DISEASE IN PATIENTS WITH MATURE T-CELL NEOPLASMS	Sanders Catherine Therese	Received

1086-P	ABNORMAL IMMUNOPHENOTYPE IS OF GREAT VALUE IN THE DIAGNOSIS OF AGGRESSIVE NATURAL KILLER CELL LEUKEMIA	Qiu Zhi-Yuan Maria	Received

1087-P	CNS PROPHYLAXIS IN PATIENTS WITH DLBCL, ARE WE TREATING OURSELVES? A RESPONSE TO THE RECENT BCSH GUIDELINE.	griffin Morag Therese	Received

1088-P	MONOCLONAL AND POLYCLONAL GAMMOPATHY MEASURED BY SERUM FREE LIGHT CHAIN AND IMMUNOFIXATION SUBDIVIDE THE CLINICAL OUTCOMES OF DIFFUSE LARGE B-CELL LYMPHOMA ACCORDING TO MOLECULAR CLASSIFICATION	Kim Yu Ri	Received

1091-P	THE ROLE OF IMAGE GUIDED CORE BIOPSY IN THE DIAGNOSIS OF HAEMATOLOGICAL MALIGNANCY	Bailey Katharine Vu	Received

1092-P	CLINICAL OUTCOME AND PROGNOSIS IN PATIENTS WITH PRIMARY SINONASAL TRACT DIFFUSE LARGE B CELL LYMPHOMA TREATED WITH R-CHOP CHEMOTHERAPY: MULTICENTER RETROSPECTIVE ANALYSIS	Lee Gyeong-Won Vu	Received

1095-P	IDENTIFYING MALIGNANT LYMPH NODES BY NANOPARTICLE MODELLING AND SIMULATIONS: A PRELIMINARY INVESTIGATION	De Tullio Giacoma	Received

1097-P	SERUM LEVELS OF SOLUBLE INTERLEUKIN-2 RECEPTOR (IL2-R), INTERLEUKIN-6 (IL-6) AND TUMOUR NECROSIS FACTOR (TNF) CORRELATE WITH ADVERSE CLINICAL FEATURES AND POOR OUTCOME IN DIFFUSE LARGE B CELL LYMPHOMA	dlouhy Ivan Giacoma	Received

1099-P	ASSOCIATION OF EPSTEIN-BARR VIRUS WITH REGRESSION AFTER WITHDRAWAL OF METHOTREXATE AND PROGRESSION OF IATROGENIC IMMUNODEFICIENCY-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS IN AUTOIMMUNE DISEASE	Fujimoto Katsuya Ri	Received

1101-P	DEVELOPMENT OF AN ALPHA/BETA T- CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION PROTOCOL FROM MATCHED RELATED AND UNRELATED DONOR GRAFTS IN PATIENTS WITH POOR RISK LEUKEMIA	de Witte Moniek	Received

1102-P	AUTOLOGOUS BONE MARROW MONONUCLEAR CELLS AND PLATELET-RICH PLASMA ENHANCED RECONSTRUCTION OF THE MAXILLOFACIAL BONY DEFECTS	Saad Abdelhamid Alaa	Received

1103-P	EPSTEIN-BARR VIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE ROLE OF CYTOMEGALOVIRUS	Liu Qifa Alaa	Received

1104-P	INTENSIFIED CONDITIONING REGIMEN WITH HIGH-DOSE ETOPOSIDE HEMATOPOIETIC STEM CELL TRANSPLANTATION YIELDED PROMISING SURVIVAL FOR HIGH-RISK AND REFRACTORY/RELAPSED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA	ZHOU Hongsheng Moniek	Received

1106-P	AUTOLOGOUS OR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HIGH-RISK AGGRESSIVE LYMPHOMAS: RETROSPECTIVE ANALYSIS IN A SINGLE CENTER IN KOREA	Yoon Jae-Ho Moniek	Received

1108-P	BEEAM (BENDAMUSTINE, ETOPOSIDE, ARA-C, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IS SAFE AND EFFECTIVE IN AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA: A PHASE II MULTICENTER STUDY	Visani G Alaa	Received

1109-P	USE OF AZATHIOPRINE FOR GRAFT-VERSUS-HOST DISEASE IS THE MAJOR RISK FOR DEVELOPMENT OF SECONDARY PRIMARY MALIGNANCIES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION	Chien Sheng Hsuan	Received

1112-P	OUTCOME OF PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA RELAPSED AFTER RELATED AND UNRELATED STEM CELL TRANSPLATATION. SINGLE CENTER EXPERIENCE.	Steinerova Katerina Moniek	Received

1113-P	UNRELATED BONE MARROW TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING REGIMEN FOR ELDERLY PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA, FEASIBILITY STUDY WITH TWO-YEAR FOLLOW UP DATA	Choi Ilseung Moniek	Received

1114-P	BIOSIMILAR VERSUS ORIGINATOR G-CSF FOR AUTOLOGOUS STEM CELL MOBILIZATION IN HEMATOLOGIC PATIENTS. AN EXPERIENCE FROM THE PHARMACOVIGILANCE GROUP OF "RETE EMATOLOGICA LOMBARDA" (FARMAREL)	PELIZZARI Anna	Received

1116-P	SEQUENTIAL CHEMOTHERAPY FOLLOWED BY REDUCED INTENSITY CONDITIONING AND ALLOGENEIC HSCT FOR HIGH RISK AML PATIENTS IN FIRST COMPLETE REMISSION: A PROSPECTIVE PILOT STUDY	MICHALLET Mauricette Maria	Received

1117-P	"REAL LIFE" USE OF PLERIXAFOR: A MULTICENTER NORTH EAST ITALY EXPERIENCE	Lessi Federica Maria	Received

1118-P	TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) WITH RITUXIMAB AND NILOTINIB, FIRST RESULTS OF ONGOING CLINICAL TRIAL.	VAN DER WAGEN	Received

1119-P	INCREASED RISK OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE IN LOW BODY MASS INDEX PATIENTS UNDERGOING HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION	chen Yao Maria	Received

1123-P	(90)Y IBRITUMOMAB TIUXETAN (ZEVALIN) FOLLOWED BY BEAM (Z-BEAM) AND AUTOLOGOUS TRANSPLANT (ASCT) IN POOR PROGNOSIS RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL): A SINGLE INSTITUTION EXPERIENCE	BOTTO Barbara Maria	Received

1125-P	PLERIXAFOR (MOZOBIL) FOR AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (ASCT) IN HARD TO MOBILIZE NHL AND HL PATIENTS: A PHASE IIB STUDY	Nagler Arnon Maria	Received

1126-P	COMPARISON OF UNRELATED CORD BLOOD WITH BONE MARROW AS A STEM CELL SOURCE FOR MYELOABLATIVE CONDITIONING TRANSPLANTATION IN PATIENTS WITH PEDIATRIC ACUTE LEUKEMIA: A RETROSPECTIVE COHORT STUDY	Arakawa Yuki Hsuan	Received

1127-P	AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: CONTRIBUTION OF NEW PHARMACOLOGICAL HAEMATOPOIESIS SUPPORT	Fominykh Mikhail Maria	Received

1128-P	ANTI-THYMOCYTE GLOBULIN (ATG) COULD IMPROVE THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE T CELL TUMORS	JUAN Yang Maria	Received

1132-P	FIRST FRENCH EXPERIENCES OF TOTAL BODY IRRADIATION USING HELICAL TOMOTHERAPY	Sun Roger WAGEN	Received

1134-P	THE ??-DNTS IN LYMPH NODES, BONE MARROW AND PERIPHERAL BLOOD OF LYMPHOMA PATIENTS: POTENTIAL PROGNOSTIC FACTOR OF CLINICAL OUTCOME.	De Tullio Giacoma	Received

1137-P	GENERATION OF MULTIVIRUS-SPECIFIC T CELLS BY A SINGLE STIMULATION OF PBMCS WITH A PEPTIDE MIXTURE UTILIZING SERUM-FREE MEDIUM	Fujita Yuriko Hsuan	Received

1138-P	GENETIC CORRECTION OF DIFFERENTLY MOBILIZED HEMATOPOIETIC STEM CELLS FROM PATIENTS WITH THALASSEMIA AND ENGRAFTMENT KINETICS AFTER XENOTRANSPLANTATION	YANNAKI Evangelia Giacoma	Received

1139-P	NEXT-GENERATION DENDRITIC CELL VACCINATION AS POSTREMISSION THERAPY FOR AML PATIENTS WITH A NON-FAVORABLE RISK PROFILE	Lichtenegger Felix Giacoma	Received

1140-P	FUNCTIONAL EVALUATION OF T-CELLS GENERATED FROM WT1-TCR TRANSDUCED HUMAN HEMATOPOIETIC STEM CELLS USING THE OP9-DL1 COCULTURE SYSTEM.	KERRE Tessa Hsuan	Received

1141-P	OPTIMIZING TUMOR-REACTIVE SINGLE-CHAIN T CELL RECEPTORS FOR ADOPTIVE T CELL TRANSFER	Hauptrock Beate Giacoma	Received

1142-P	COMBINING ADOPTIVE TCR IMMUNOTHERAPY AND ARGININE DEPLETION IN OSTEOSARCOMA XENOGRAFT MODEL	Echchannaoui Hakim Giacoma	Received

1143-P	HDAC6 INHIBITION AUGMENTS THE EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES BY UP-REGULATING CD20 LEVEL IN MALIGNANT B-CELLS	Bobrowicz Malgorzata Giacoma	Received

1144-P	ADOPTIVE CIK CELLS IN PATIENTS WITH LEUKEMIA RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	li Qing	Received

1145-P	CYTOMEGALOVIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES RESTRICTED TO HLA-A2 OR HLA-A24 CAN BE EFFICIENTLY GENERATED BY USING GENE-ENGINEERED ARTIFICIAL ANTIGEN-PRESENTING CELLS	Ogasawara Masahiro	Received

1146-P	DESIGNING TCR SPECIFIC FOR HUMAN MDM2 TUMOR-ASSOCIATED ANTIGEN FOR ADOPTIVE IMMUNOTHERAPY AGAINST MELANOMA AND MULTIPLE MYELOMA	Amann Eva Giacoma	Received

1147-P	AN EFFICIENT AND COST EFFECTIVE METHOD FOR THE GENERATION OF CLINICALLY RELEVANT NUMBERS OF MYELOID CORD BLOOD-DERIVED DENDRITIC CELLS BY EMPLOYING CLINICALLY APPROVED AGENTS	Kaloyannidis Panayotis WAGEN	Received

1148-P	HYPOMETHYLATING AGENT AZACITIDINE INDUCES FOXP3 NEGATIVE HLA-G EXPRESSING IMMUNOREGULATORY T CELLS.	Stamou Panagiota Giacoma	Received

1149-P	IMMUNOPHENOTYPIC PROFILE AND FUNCTIONAL CHARACTERISTICS OF NK CELLS EXPANDED FROM CYTOMEGALOVIRUS SEROPOSITIVE AND SERONEGATIVE DONORS: IMPLICATIONS FOR NEW STRATEGIES OF ADOPTIVE CELLULAR THERAPIES	Peragine Nadia Giacoma	Received

1150-P	GENERATION OF PATIENT-INDIVIDUALIZED AML-REACTIVE DONOR CD8+ T CELLS UNDER GMP-COMPLIANT CONDITIONS FOR ADOPTIVE TRANSFER IN LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Chung-Ueck Boidinh WAGEN	Received

1151-P	LOW-DOSE BORTEZOMIB SENSITIZES MULTIPLE MEYLOMA TO GAMMA-DELTA T CELLS LYSIS	Niu Chao Hsuan	Received

1152-P	HUMAN MONOCYTE-DERIVED DENDRITIC CELLS EXPOSED TO HYPERTHERMIA SHOW A DISTINCT GENE EXPRESSION PROFILE AND SELECTIVE UPREGULATION OF IGFBP-6	Liso Arcangelo Hsuan	Received

1153-P	ROLE OF LONG PENTRAXIN 3 (PTX3) IN WOUND CLOSURE INDUCED BY BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS	Cappuzzello Claudia Giacoma	Received

1155-P	QUANTITATIVE T2* MRI FOR BONE MARROW IRON OVERLOAD ASSESSMENT IN A LARGE COHORT OF THALASSEMIA MAJOR PATIENTS.	Meloni Antonella	Received

1156-P	BONE MINERAL DENSITY IMPROVEMENT IN PATIENTS WITH THALASSEMIA MAJOR ON LONG-TERM CHELATION THERAPY WITH DEFERASIROX	Casale Maddalena Giacoma	Received

1158-P	18 MONTHS DATA OF A RANDOMIZED CONTROLLED TRIAL OF COMBINED DEFERIPRONE (DFP) AND DEFERASIROX (DFX) VERSUS COMBINED DEFERIPRONE AND DEFEROXAMINE (DFO), IN YOUNG ?-THALASSEMIA MAJOR	ADLY Amira	Received

1159-P	HIGH PREVALENCE, EXTENT AND SEVERITY OF SPINAL DEGENERATIVE CHANGES IN ADULT THALASSAEMIA PATIENTS PRESENTING WITH BACK PAIN	SHAH Farrukh	Received

1160-P	PEDIATRIC THALASSEMIA MAJOR PATIENTS : PROSPECTIVE COMPARISON OF CHELATION TREATMENTS	Meloni Antonella Hsuan	Received

1161-P	TISSUE IRON DEPOSITION AND MARKERS OF GLUCOSE DYSREGULATION IN THALASSEMIA MAJOR	Aydinok Yesim Giacoma	Received

1162-P	PRESENCE OF THE IVS1-6 MUTATED ALLELE PREDISPOSES PATIENTS WITH MAJOR ? THALASSAEMIA TO EXTRAMEDULLARY HAEMATOPOISES	Adamidou Despoina Giacoma	Received

1163-P	BONE MINERALIZATION AND ENDOCRINE DISEASE IN PATIENTS WITH BETA-THALASSEMIA INTERMEDIA (TI).	Marcon Alessia Giacoma	Received

1164-P	INVESTIGATION OF RENAL FUNCTION DISORDERS IN PATIENTS WITH THALASSEMIA AND THEIR RELATION WITH IRON OVERLOAD	deveci Burak WAGEN	Received

1165-P	ASSOCIATION OF OR51B2 SEQUENCE VARIATIONS WITH RESPONSE TO HYDROXYUREA THERAPY IN IRANIAN PATIENTS AFFECTED WITH BETA-THALASSEMIA INTERMEDIA	KARIMI Mehran Hsuan	Received

1166-P	LEFT VENTRICULAR GLOBAL FUNCTION INDEX BY CMR IS MORE STRONGLY ASSOCIATED TO DIFFERENT PATTERNS OF MYOCARDIAL IRON OVERLOAD THAN THE GLOBAL SYSTOLIC FUNCTION	Meloni Antonella Hsuan	Received

1167-P	PROSPECTIVE MRI STUDY IN PEDIATRIC THALASSEMIA MAJOR (TM) PATIENTS IN THE MIOT NETWORK: A TOOL TO STRENGTHEN MEDICAL DECISIONS.	Meloni Antonella Hsuan	Received

1168-P	THE ROLE OF LEFT VENTRICULAR GLOBAL FUNCTION INDEX FOR THE PREDICTION OF CARDIAC COMPLICATIONS IN THALASSEMIA MAJOR	Meloni Antonella Hsuan	Received

1169-P	RIGHT VENTRICULAR WALL MOTION ABNORMALITIES IN PATIENTS WITH THALASSEMIA MAJOR AND INTERMEDIA	Meloni Antonella Hsuan	Received

1170-P	TROPONINE T AS A MARKER OF CARDIAC IMPAIRMENT IN PATIENTS SUFFERING THALASSEMIA	Vetro Calogero Hsuan	Received

1173-P	CLINICAL HETEROGENEITY OF AUTOIMMUNE HEMOLYTIC ANEMIA: A GIMEMA STUDY OF 308 PATIENTS	Barcellini Wilma Giacoma	Received

1174-P	REDUCED 25-OH VITAMIN D LEVELS IN PATIENTS WITH AUTOIMMUNE CITOPENIAS: CORRELATION WITH HAEMATOLOGICAL PARAMETERS AND CLINICAL SEVERITY	Fattizzo Bruno Giacoma	Received

1176-P	SIROLIMUS AS TREATMENT OF STEROID DEPENDENT/RESISTANT AUTOIMMUNE HAEMOLYTIC ANEMIA/PURE RED CELL ANEMIA IN CHILDREN	Miano Maurizio Hsuan	Received

1177-P	ANALYSIS OF CAUSES OF ANAEMIA FOUND IN A GENERAL PRACTICE POPULATION: PREVALENCE AND SURVIVAL	Stouten Karlijn Giacoma	Received

1178-P	RENAL FUNCTIONAL AND STRUCTURAL INTEGRITY IN CHILDREN WITH IRON DEFICIENCY ANEMIA: RESPONSE TO IRON THERAPY	El-Farrash Rania Hsuan	Received

1179-P	MULTIFACTORIAL PATHOGENESIS OF ANEMIA IN PREGNANCY	Demikhov Valerii Hsuan	Received

1181-P	THROMBOEMBOLISM OCCURRED REGARDLESS OF HEMOLYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA– A PROSPECTIVE STUDY OF 464 PATIENTS IN A MULTICENTER CHINESE REGISTRY	Zhang Danyu WAGEN	Received

1182-P	NEW RED BLOOD CELL AUTOMATED PARAMETERS FOR IRON DEFICIENCY SCREENING IN CHRONIC INFLAMMATORY DISEASE	Lazarova Elena Giacoma	Received

1184-P	MICROCYTIC ANAEMIA AND IRON METABOLISM IN ERYTHROPOIETIC PROTOPORPHYRIA	spinelli Diana Giacoma	Received

1185-P	SIGNIFICANT IMPACT OF IRON CHELATION AFTER ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANTATION ON DISEASE RECURRENCE: POTENTIAL ANTI-LEUKEMIC ACTIVITY	MICHALLET Mauricette	Received

1186-P	INVESTIGATION ON THE EARLIEST SIGN OF INVASIVE PULMONARY ASPERGILLOSIS (IPA) AND THE ONSET, WITH ROUTINE NON-PYREXIA PHASE CT BASED DIAGNOSTIC STRATEGY, A COHORT STUDY	Kyo Kouhei Giacoma	Received

1189-P	AEROSOLIZED LIPOSOMAL AMPHOTERICIN-B TO PREVENT INVASIVE PULMONARY ASPERGILLOSIS IN ACUTE MYELOID LEUKEMIA. EFFICACY AND COST-EFFECTIVENESS IN REAL-LIFE.	Chong Ga-Lai WAGEN	Received

1190-P	HIGH RISK OF INVASIVE FUNGAL INFECTIONS (IFI) IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS RECEIVING INDUCTION AND SALVAGE CHEMOTHERAPY WITH ITRACONAZOLE PROPHYLAXIS – TIME TO CHANGE GAME PLAN	Wong Gee Chuan	Received

1191-P	A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS OF ANTIFUNGAL TREATMENTS IN ONCO-HEMATOLOGIC PATIENTS	Fracchiolla Nicola Chuan	Received

1194-P	IMPACT OF TOLL-LIKE RECEPTOR 4 POLYMORPHISMS ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Schnetzke Ulf Giacoma	Received

1195-P	THE EXPRESSION OF TOLL-LIKE RECEPTORS AND DEVELOPMENT OF SEVERE SEPSIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIAS.	Rybka Justyna Giacoma	Received

1196-P	ANTIBACTERIAL PROPHYLAXIS AND EMERGING RESISTANT STRAINS IMPACT ON EPIDEMIOLOGY AND OUTCOME OF BLOODSTREAM INFECTIONS IN ACUTE LEUKAEMIA: A PROSPECTIVE STUDY BY THE RETE EMATOLOGICA LOMBARDA (REL)	Cattaneo Chiara Giacoma	Received

1198-P	THE INCREASING PROBLEM OF BLOODSTREAM INFECTIONS CAUSED BY MULTI-DRUG RESISTANT BACTERIA IN HEMATOLOGIC AND HSCT PATIENTS.	Candoni Anna Chuan	Received

1200-P	CLOSTRIDIUM DIFFICILE INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY IN CZECH AND SLOVAK REPUBLIC – A RETROSPECTIVE ANALYSIS	Palackova Martina WAGEN	Received

1202-P	A SINGLE-INSTITUTION EXPERIENCE OF PERIPHERAL INSERTED CENTRAL VENOUS CATHETERS IN ONCO-HEMATOLOGIC PATIENTS	Fracchiolla Nicola Giacoma	Received

1208-P	CLINICAL FEATURES, GENETICS AND OUTCOME OF PEDIATRIC PATIENTS WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN KOREA: REPORT OF A NATIONWIDE SURVEY FROM KOREA HISTIOCYTOSIS WORKING PARTY	Lee Seong Wook	Received

1212-P	OXIDANT STATUS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) AND THE ROLE OF AN ADJUVANT ANTIOXIDANT THERAPY.	elhenawy Yasmine	Received

1213-P	EPIDEMIOLOGY OF INCIDENT IMMUNE THROMBOCYTOPENIA IN FRANCE: A NATIONWIDE POPULATION-BASED STUDY.	Moulis Guillaume Wook	Received

1214-P	RITUXIMAB REVERSED THE INCREASE IN SPLENIC T FOLLICULAR HELPER CELLS DURING IMMUNE THROMBOCYTOPENIA.	Audia Sylvain Wook	Received

1215-P	SUSTAINED RESPONSE AFTER THROMBOPOIETIN RECEPTOR AGONISTS DISCONTINUATION IN 5 PATIENTS AFFECTED BY PRIMARY IMMUNE THROMBOCYTOPENIA	Santoro Cristina Wook	Received

1216-P	NOVEL MUTATIONS AT GPIIB/GPIIIA GENES FROM TURKISH PATIENTS WITH GLANZMANN THROMBASTHENIA SYNDROME	Özkan Didem (Torun)	Received

1217-P	NEXT GENERATION SEQUENCING OF NBEAL2 GENE MUTATIONS IN GRAY PLATELET SYNDROME	Ma Edmond (Torun)	Received

1218-P	IS HIGHER IL-21 LEVEL PREDICTIVE OF RELAPSES IN IMMUNE THROMBOCYTOPENIA AND IS IT ASSOCIATED WITH ACTIVATION OF THE COMPLEMENT SYSTEM?	Pamuk Gulsum (Torun)	Received

1220-P	CLINICO-PATHOLOGIC FEATURES OF COMMON VARIABLE IMMUNODEFICIENCY (CVID) PATIENTS MANIFESTING CYTOPENIAS	Srirangam Vinaya (Torun)	Received

1221-P	PRIMARY VERSUS SECONDARY ITP IN ADULTS ; A COMPARATIVE ANALYSIS OF CLINICAL AND LABORTORY ATTRIBURTES IN NEWLY DIAGNOSED PATIENTS IN AN ASIAN POPULATION.	sultan Dr	Received

1222-P	ROUTINE BONE MARROW EXAMINATIONS MAY NOT BE NECESSARY IN THE EVALUATION OF PATIENTS WITH INMUNE THROMBOCYTOPENIA	OLIVERA SUMIRE Pavel	Received

1223-P	RITUXIMAB SALVAGE THERAPY IN ADULTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA: EFFICACY AND SAFETY	Reboursiere Emilie WAGEN	Received

1224-P	INTERNATIONAL ITP REGISTRY WITH FOCUS ON THE ASIA PACIFIC REGION: PRELIMINARY FINDINGS OF EPIDEMIOLOGICAL AND CLINICAL DATA	McIntyre Kiara Pavel	Received

1225-P	CMV INFECTION DOES NOT HAVE AN IMPACT ON BLEEDING MANIFESTATIONS OR PROGNOSIS OF IDIOPATHIC THROMBOCYTOPENIA	Ragab Iman Pavel	Received

1226-P	THE RISK OF CANCER IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP): A NATIONWIDE POPULATION-BASED STUDY	Hu Ming-Hung Pavel	Received

1227-P	HELICOBACTER PYLORI INFECTION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA.	Jimenez-Barcenas Reyes Pavel	Received

1229-P	CLINICAL ANALYSIS OF EFFECT OF HELICOBACTER PYLORI ERADICATION IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA	Hongqiong Fan	Received

1236-P	THE EFFECT OF MORBID OBESITY ON THROMBIN GENERATION AND SENSITIVITY TO THE ANTICOAGULANT ACTIVATED PROTEIN C IN PREGNANT WOMEN	Kevane Barry Pavel	Received

1237-P	HYPOXIA CONTRIBUTES TO PROCOAGULANT ACTIVITY OF BREAST CANCER CELLS	cui Xueyan Pavel	Received

1238-P	IMPACT OF RECOMBINANT THROMBOMODULIN ON THE OUTCOME OF NEONATES WITH DISSEMINATED INTRAVASCULAR COAGULATION DIFFERS ACCORDING TO APGAR SCORE	Yagasaki Hiroshi Pavel	Received

1240-P	HIGH INCINDENE OF CEREBRAL LEISIONS IN ADULT PATIENTS WITH BETA-THALASSEMIA MAJOR	Stark Pinhas	Received

1241-P	PLATELET THROMBUS FORMATION UNDER FLOW CONDITION IS INCREASED IN MYELOPROLIFERATIVE NEOPLASMS (MPNS)	Tessarolo Serena Pavel	Received

1243-P	INCREASED FIBRINOGEN LEVELS AND TESTOSTERONE DEFICIENCY HAVE AN ADDITIVE DETRIMENTAL EFFECT ON CAROTID WALL THICKNESS IN ESSENTIAL HYPERTENSIVE PATIENTS	Pallantza Zoi Pina	Received

1244-P	FUNCTIONAL EVALUATION OF TISSUE FACTOR IN FLOW-DEPENDENT THROMBUS FORMATION ON IMMOBILIZED VON WILLEBRAND FACTOR	Sugimoto Mitsuhiko	Received

1245-P	CLINICAL SIGNIFICANCE OF THE NEUTROPHIL-LYMPHOCYTE RATIO IN VENOUS THROMBOEMBOLISM PATIENTS WITH LUNG CANCER	Lee Gyeong-Won Pavel	Received

1246-P	PATTERNS OF DIFFERING THROMBIN GENERATION AND SENSITIVITY TO THE ANTICOAGULANT ACTIVATED PROTEIN C IN PATIENTS WITH MYELOMA AND MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE.	Crowley Maeve P	Received

1248-P	HAEMATOLOGICAL MORBIDITY IN OBSTETRIC PATIENTS WITH CARDIAC DISEASE	Kevane Barry Pavel	Received

1249-P	PREVALENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A DANISH FOLLOW-UP STUDY	Severinsen Marianne Tang	Received

1251-P	A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF THE INCIDENCE OF MAJOR BLEEDING IN OVER 1000 PATIENTS COMMENCED ON RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION AND VENOUS THROMBOEMBOLISM	Jenkins Stephen P	Received

1253-P	MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY IN PATIENTS WITH ACUTE UNPROVOKED DEEP VEIN THROMBOSIS AND DURING THE COURSE OF ONE YEAR	THALER Johannes	Received

1254-P	DEVELOPMENT OF A PHARMACOGENETIC-BASED WARFARIN DOSING ALGORITHM IN BRAZILIAN PATIENTS	Santos Paulo	Received

1255-P	CURRENT MANAGEMENT AND OUTCOMES OF VENOUS THROMBOEMBOLISM IN AUSTRALIA: INITIAL RESULTS FROM THE VENOUS THROMBOEMBOLISM COHORT STUDY	Aoki Naomi Tang	Received

1256-P	IN-VIVO REVERSAL OF THE ANTICOAGULANT EFFECT OF APIXABAN WITH 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE	Cheung Yuk Wah	Received

1257-P	EFFICACY OF REPEAT DUPLEX ULTRASOUND IN PATIENTS WITH SUSPECTED DEEP VENOUS THROMBOSIS	Scholtes Brian Tang	Received

1258-P	SPANISH REGISTRY OF THROMBOEMBOLIC DISEASE (TD) RELATED WITH HORMONAL THERAPY, PREGNANCY, OBSTETRICS COMPLICATIONS OR ASSISTED REPRODUCTIVE TECHNIQUES IN WOMEN (ARP): RESULTS OF THE TEAM PROJECT	santamaria Amparo	Received

1259-P	RETROSPECTIVE AUDIT OF INCIDENCE OF PICC LINE RELATED DEEP VEIN THROMBOSIS IN HAEM-ONCOLOGY PATIENTS	Sriskandarajah Priya	Received

1260-P	THREE YEAR MORTALITY ASSOCIATED WITH VENOUS THROMBOEMBOLISM (VTE): COMPARISON OF HOSPITAL ACQUIRED, COMMUNITY ACQUIRED AND INCIDENTAL FINDINGS	Rowswell Huw Tang	Received

1261-P	INFLAMMATORY RESPONSE AMONG PATIENTS WITH SUSPECTED VENOUS THROMBOEMBOLISM	Mosevoll Knut	Received

1262-P	REDUCTIONS IN VENOUS THROMBOEBOLISM EVENTS, ASSOCIATED WITH RADIOLOGICAL DATA PROVIDING REAL-TIME FEEDBACK TO CLINICIANS ABOUT HOSPITAL ACQUIRED THROMBOSIS, GIVEN INADEQUATE PREVENTATIVE MEASURES	Rowswell Huw Anders	Received

1264-P	LONG-TERM OUTCOME OF NON-CENTRAL-VENOUS-LINE-RELATED DEEP VEIN THROMBOSES LOCATED AT LOWER LIMBS IN CHILDREN	Pergantou Helen Anders	Received

1265-P	MORTALITY AND INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND RELATION TO LABORATORY BIOMARKERS: AN UPDATE OF A SINGLE CENTER STUDY	Elmoamly Shereef	Received

1266-P	GENETIC AND ACQUIRED PREDICTORS OF POSTTHROMBOTIC SYNDROME IN YOUNG PATIENTS WITH DVT IN THE NORTH-WEST REGION OF RUSSIA	Demyanenko Anna	Received

1267-P	EFFICACY, SAFETY AND CLINICAL MANAGEMENT OF THE NEW GENERATION ORAL ANTICOAGULANTS (NOAS) IN THE CLINICAL PRACTICE: "THE REAL LIFE COHORT STUDY".	OLIVERA SUMIRE Pavel	Received

1268-P	COST-EFFECTIVENESS OF EDOXABAN, APIXABAN, RIVAROXABAN AND DABIGATRAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION	Marchetti Monia Anders	Received

1269-P	ECONOMIC VALUE CREATED BY ADDING RITUXIMAB TO CHEMOTHERAPY IN THE UNITED STATES FROM 1998-2013	Reyes Carolina Anders	Received

1271-P	IS OBINUTUZUMAB COST-EFFECTIVE FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES?	Reyes Carolina Wah	Received

1272-P	HOME CARE MANAGEMENT FOR HEMATOLOGICAL PATIENTS: RESULTS OF A SURVEY CONDUCTED ON A REGIONAL SCALE BY THE R.E.D.E.R. NETWORK	Alfieri Pierluigi Anders	Received

1273-P	SENSITIVITY COST ANALYSIS OF TYROSINE KINASE INHIBITORS IN PHARMACOECONOMIC MODELING OF CML TREATMENT	SHUVAEV Vasily Wah	Received

1274-P	DIRECT COST ANALYSIS ABOUT THE THREE CHELATORS FOR THE TREATMENT OF THALASSEMIA PATIENTS WITH CHRONIC IRON OVERLOAD: AN ITALIAN PERSPECTIVE FROM THE MIOT NETWORK	Meloni Antonella Pavel	Received

1276-P	PATTERN OF ADVERSE DRUG REACTIONS IN ONCO-HEMATOLOGIC PATIENTS: RESULTS FROM THE ITALIAN PHARMACOVIGILANCE PROJECT NAMED "FARMAREL"	Fracchiolla Nicola Wah	Received

1277-P	PLERIXAFOR IS COST-EFFECTIVE FOR FIRST LINE STEM CELL MOBILISATION: INDIVIDUAL PATIENT COSTING ANALYSIS OF THE LIVERPOOL PHANTASTIC TRIAL	Haycox Alan Anders	Received

1279-P	PREVENTABILITY ASSESSMENT OF ADVERSE DRUG REACTIONS IN ONCOHEMATOLOGIC PATIENTS: HEMATOLOGY CLINICAL JUDGMENT COMPARED TO SCHUMOCK AND THORNTON EXPLICIT CRITERIA	Fracchiolla Nicola Wah	Received

1280-P	COMPARATIVE ANALYSIS OF ADVERSE REACTIONS ARISING FROM THE ADMINISTRATION OF CONVENTIONAL CYTOTOXIC DRUGS AND RECENT TARGETED AGENTS, ALONE OR IN ASSOCIATION, IN ONCOHEMATOLOGIC PATIENTS	Fracchiolla Nicola Anders	Received

1281-P	SOCIETAL ECONOMIC BURDEN OF IRON DEFICIENCY INDUCED FATIGUE	Blank Patricia R.	Received

1282-P	WILL SUBSTITUTION OF TKI GENERIC BRING THE CML TREATMENT FUTURE TO THE PAST? PHARMACOECONOMIC MODELING OF CML TREATMENT WITH OWN GENERIC USE EXPERIENCE.	SHUVAEV Vasily R.	Received

2444-LB	ACCELERATION OF BCR-ABL+ LEUKEMIA INDUCED BY DELETION OF JAK2	Eva Grundschober	Received

2446-LB	IRON-INDUCED EPIGENETIC ABNORMALITY OF MOUSE BONE MARROW THROUGH ABERRANT ACTIVATION OF ACONITASE AND ISOCITRATE DEHYDROGENASE WITHOUT GENE MUTATION: ANALYSIS BY HIGH THROUGHPUT SEQUENCER AND GC-MS.	Masayo Yamamoto	Received

2448-LB	RESPONSE TO LISINOPRIL IN PATIENTS WITH SICKLE CELL ANEMIA AND PROTEINURIA	Aamer Aleem	Received

2450-LB	ICARS: ENGINEERED SAFETY FOR T CELL IMMUNOTHERAPY	Raffaella Pippa	Received

2451-LB	PRETREATMENT D-2-HYDROXYGLUTARATE SERUM LEVELS PREDICT OUTCOME IN IDH1-MUTATED ACUTE MYELOID LEUKEMIA	Christoph Heilig	Received

19th Congress of EHA

12 - 15 June 2014 Milan

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 12/06/2014 TO 15/06/2015

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access